var title_f21_13_21712="RTT late deterioration";
var content_f21_13_21712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rett syndrome, late deterioration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This woman with RTT no longer ambulated and had severe motor dysfunction: scoliosis, dystonia, lack of facial expression are characteristic of this phase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright &copy; 1997 Medscape.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21712=[""].join("\n");
var outline_f21_13_21712=null;
var title_f21_13_21713="Pathologic skin picking abdomen";
var content_f21_13_21713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathologic skin picking",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angulated, linear, and sharply demarcated erosions, ulcerations, and purpuric patches on the abdomen of a healthy 15-year-old girl with a history of acute anxiety. The eruption cleared completely following mental health counseling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21713=[""].join("\n");
var outline_f21_13_21713=null;
var title_f21_13_21714="Patient information: Dilated cardiomyopathy (The Basics)";
var content_f21_13_21714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15752\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/29/12757\">",
"         Heart with dilated cardiomyopathy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/7/39039\">",
"          Holter monitor",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/28/35266\">",
"         Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/17/44305\">",
"         Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/49/18197\">",
"         Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dilated cardiomyopathy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dilated-cardiomyopathy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1731152970\">",
"      <span class=\"h1\">",
"       What is dilated cardiomyopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dilated cardiomyopathy is a condition in which the heart muscle weakens and one or more of the spaces inside the heart (called &ldquo;chambers&rdquo;) gets bigger (",
"      <a class=\"graphic graphic_figure graphicRef58474 \" href=\"UTD.htm?12/29/12757\">",
"       figure 1",
"      </a>",
"      ). When this happens, the heart sometimes becomes unable to pump blood as well as it should. This can lead to a problem called &ldquo;heart failure.&rdquo;",
"     </p>",
"     <p>",
"      The term &ldquo;heart failure&rdquo; is misleading. If your doctor tells you that you have heart failure, it does not mean your heart has stopped working. It just means that your heart has trouble keeping up with your body&rsquo;s demand for blood and oxygen (which is carried in the blood). But it is still working.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731152977\">",
"      <span class=\"h1\">",
"       What are the symptoms of dilated cardiomyopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;At first, dilated cardiomyopathy often does not cause symptoms. But as the condition gets worse, it can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing, especially during exercise",
"       </li>",
"       <li>",
"        Trouble breathing when lying down or asleep",
"       </li>",
"       <li>",
"        Trouble doing physical activity or exercise",
"       </li>",
"       <li>",
"        Swelling in the feet, ankles, or legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731152984\">",
"      <span class=\"h1\">",
"       Is there a test for dilated cardiomyopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have cardiomyopathy, he or she might order one or more of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         A chest X-ray",
"        </strong>",
"        &ndash; An X-ray can show if your heart is enlarged.",
"       </li>",
"       <li>",
"        <strong>",
"         An electrocardiogram (ECG or EKG)",
"        </strong>",
"        &mdash; This test measures the electrical activity in your heart. It can show if your heart beats in a normal rhythm and if you have had a heart attack in the past. Some people wear a device all day that takes an ECG reading (",
"        <a class=\"graphic graphic_figure graphicRef76605 \" href=\"UTD.htm?38/7/39039\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         An echocardiogram (or &ldquo;echo&rdquo; for short)",
"        </strong>",
"        &mdash; An echo uses sound waves to create an image of the heart. This test allows doctors to measure the walls and chambers of the heart, see how the heart is pumping, and see how the heart valves are working. (Heart valves are flaps of tissue that open and close like swinging doors. They help keep blood flowing in one direction.)",
"       </li>",
"       <li>",
"        <strong>",
"         A stress test &mdash;",
"        </strong>",
"        During a stress test, you might be asked to run or walk on a treadmill while you also have an ECG. Physical activity increases the heart&rsquo;s need for blood. This test helps doctors see if the heart is getting enough blood. If you cannot walk or run, your doctor might do this test by giving you a medicine to make your blood vessels widen or make your heart pump faster.",
"       </li>",
"       <li>",
"        <strong>",
"         Cardiac catheterization",
"        </strong>",
"        &mdash; Cardiac (heart) catheterization is also known as cardiac &ldquo;cath.&rdquo; During this test, the doctor inserts a thin tube (called a catheter) into a large artery in your leg and threads it up to your heart. The doctor uses this tube to measure the pressure inside your arteries and heart. The doctor might also inject a dye into your arteries that shows up on an X-ray. This part of the test is called &ldquo;coronary angiography.&rdquo; Coronary angiography can show whether any of the arteries in your heart are clogged. In some cases, the doctor will also take a tiny piece of heart muscle (a &ldquo;biopsy&rdquo;). This can help the doctor find the cause of your cardiomyopathy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731152991\">",
"      <span class=\"h1\">",
"       How is dilated cardiomyopathy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for dilated cardiomyopathy depends on what is causing it and how severe it is. For example, in people who have cardiomyopathy caused by alcohol use, an important part of treatment is avoiding alcohol. If dilated cardiomyopathy is causing heart failure, the treatment is generally similar to that for other causes of heart failure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731152998\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/13/21714?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15752 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21714=[""].join("\n");
var outline_f21_13_21714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731152970\">",
"      What is dilated cardiomyopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731152977\">",
"      What are the symptoms of dilated cardiomyopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731152984\">",
"      Is there a test for dilated cardiomyopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731152991\">",
"      How is dilated cardiomyopathy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731152998\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/29/12757\">",
"      Heart with dilated cardiomyopathy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/7/39039\">",
"       Holter monitor",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_13_21715="Intravenous copper: Drug information";
var content_f21_13_21715=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Intravenous copper: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/26/30115?source=see_link\">",
"    see \"Intravenous copper: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10414479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Trace Element, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10414675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Supplementation:",
"     </b>",
"     I.V. (incorporated into parenteral nutrition): 0.3-0.5 mg/day (ASPEN, 2002);  0.5-1.5 mg/day (manufacturer's product labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High output intestinal fistula: Some clinicians may use twice the recommended daily allowance (ASPEN, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10414674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/26/30115?source=see_link\">",
"      see \"Intravenous copper: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Supplementation:",
"     </b>",
"     Infants and Children: I.V. (incorporated into parenteral nutrition): 20 mcg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10414676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution. Start at the low end of dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10414677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; contains aluminum.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10414678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; dosage reduction may be required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10414685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.4 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10414477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10414679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be diluted. Do not administer I.M. or by direct I.V. injection; acidic pH of the solution may cause tissue irritation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10414480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplement to intravenous solutions given for total parenteral nutrition (TPN) to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13934215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cupric sulfate may be confused with calcium gluconate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13897405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Generally well tolerated; excessive copper levels may result in the following adverse effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Hepatic dysfunction (including hepatic necrosis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10414585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10414586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal fistulae: Patients with high output intestinal fistulae may require a larger dose than the recommended daily allowance (ASPEN, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment (eg, impaired biliary excretion or cholestatic liver disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Wilson&rsquo;s disease: Administration not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; TPN preparation: Copper ion may degrade ascorbic acid in TPN solutions. To avoid loss, add multivitamin additives to TPN solutions immediately prior to infusion or add to separate TPN solution container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aluminum: Contains aluminum; use caution with impaired renal function and in premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10486767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: Copper may decrease the serum concentration of Ascorbic Acid.  Management: To minimize the risk for ascorbic acid degradation, add multivitamin product to TPN solution immediately prior to infusion or administer multivitamin and copper in separate containers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10414481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10414482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. It is not known whether administration to a pregnant woman can cause fetal harm or can affect reproductive capacity.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10414483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10414584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Copper Chloride Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/mL (10 mL): $2.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Copper Sulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/mL (10 mL): $4.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10414683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Twice monthly serum assays for copper and/or ceruloplasmin in long-term TPN patients, patients with hepatic failure or high output gastrointestinal fistulas",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10414669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum levels: 0.7-1.5 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10414667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Copper is an essential nutrient which serves as a cofactor for serum ceruloplasmin, an oxidase necessary for proper formation of the iron carrier protein, transferrin. It also helps maintain normal rates of red and white blood cell formation and helps prevent development of deficiency symptoms: Leukopenia, neutropenia, anemia, depressed ceruloplasmin levels, impaired transferring formation, secondary iron deficiency and osteoporosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10414670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion: Bile (primarily); Intestinal wall; Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ASPEN Board of Directors and the Clinical Guidelines Task Force, &ldquo;Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2002, 26(1 Suppl):1-138.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21715/abstract-text/11841046/pubmed\" id=\"11841046\" target=\"_blank\">",
"        11841046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15582 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21715=[""].join("\n");
var outline_f21_13_21715=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414479\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414675\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414674\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414676\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414677\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414678\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414685\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414477\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414679\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414480\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13934215\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13897405\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414585\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414586\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299092\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10486767\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414481\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414482\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414483\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414584\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322859\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414683\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414669\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414667\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414670\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15582|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/26/30115?source=related_link\">",
"      Intravenous copper: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_13_21716="Idiopathic hemosiderosis PA";
var content_f21_13_21716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic pulmonary hemosiderosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Film A shows the posteroanterior radiograph of a 32 year old woman with hemoptysis due to her first attack of idiopathic pulmonary hemosiderosis. There is diffuse, ground-glass opacification in both lungs. Film B taken one month later shows complete regression of the opacities following treatment with prednisolone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nils Milman, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21716=[""].join("\n");
var outline_f21_13_21716=null;
var title_f21_13_21717="Total knee replacement (arthroplasty)";
var content_f21_13_21717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21717/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21717/contributors\">",
"     Gregory M Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21717/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21717/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21717/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21717/contributors\">",
"     Jerry M Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/13/21717/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total knee replacement, or total knee arthroplasty, is a surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses).",
"   </p>",
"   <p>",
"    A normal knee functions as a hinge joint between the upper leg bone (femur) and the lower leg bones (tibia and fibula) (",
"    <a class=\"graphic graphic_figure graphicRef57878 \" href=\"UTD.htm?17/11/17584\">",
"     figure 1",
"    </a>",
"    ). The surfaces where these bones meet can become worn out over time, often due to arthritis or other conditions, which can cause pain and swelling.",
"   </p>",
"   <p>",
"    More detailed information about knee replacement is available by subscription. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=see_link\">",
"     \"Total knee arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REASONS FOR KNEE REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total knee replacement is one option to relieve pain and to restore function to an arthritic knee. The most common reason for knee replacement is that other treatments (weight loss, medicines, and injections) have failed to relieve arthritis-associated knee pain.",
"   </p>",
"   <p>",
"    The goal of knee replacement is to relieve pain, to improve quality of life, and to maintain or improve knee function. The procedure is performed on people of all ages, with the exception of children, whose bones are still growing.",
"   </p>",
"   <p>",
"    Approximately 700 thousand knee replacement procedures are performed annually in the US. This number is projected to increase to 3.48 million procedures per year by 2030 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21717/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO KNEE REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While total knee replacement can be helpful under the right circumstances, you should discuss the risks, benefits, and alternatives with a doctor. Alternatives to total knee replacement include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonsurgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsurgical treatment methods are initially recommended for patients with osteoarthritis or inflammatory arthritis. This includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Medications, including over-the-counter and prescription. These include pain relievers such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and antiinflammatory drugs such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      . Patients should discuss use of these medications with their primary care provider and pharmacist to be sure the risk of side effects is acceptably low. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Knee bracing or shoe inserts, both of which may help align the knee and balance the weight on the joint",
"     </li>",
"     <li>",
"      Injections, either with a cortisone-like drug or a hyaluronic acid derivative (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=see_link\">",
"       \"Patient information: Knee pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients with rheumatoid or other inflammatory arthritis should try physical therapy and medicines before considering total knee replacement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arthroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopy is a minimally invasive surgical procedure in which a doctor examines the inside of a joint with a device called an arthroscope. The doctor can repair any damage through small surgical incisions in the skin. Arthroscopy is only helpful for a certain type of knee problems. Arthroscopic surgery has not demonstrated significant benefit for patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21717/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Osteotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteotomy is a surgical procedure that involves cutting the leg bone, realigning it, and allowing it to heal. It is used to shift weight from a damaged part of the knee to a normal or less damaged one. Osteotomy is not recommended for patients older than 60 years of age or for those with inflammatory arthritis (such as rheumatoid arthritis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Partial knee replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A &ldquo;partial&rdquo; or unicompartmental knee replacement involves replacing only one part of the knee joint. There is debate about the benefit of partial knee replacement compared with total knee replacement, but some studies have shown favorable results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21717/abstract/3\">",
"     3",
"    </a>",
"    ]. You should talk to your doctor about the possible risks and benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THE KNEE REPLACEMENT PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knee replacement is performed in an operating room after you are given anesthesia. The surgery takes two to three hours. After surgery, you will be monitored in a recovery area for several hours, until the effects of the anesthesia wear off.",
"   </p>",
"   <p>",
"    Most people stay in the hospital for two to four nights after surgery. During this time, you will be given pain medicines.",
"   </p>",
"   <p>",
"    Blood clots in the legs (called deep vein thromboses) are a common concern after knee replacement surgery. To reduce the risk of blood clots:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      You will take a medicine, either as a pill or a shot. Most patients continue to take this medicine for a few weeks after surgery.",
"     </li>",
"     <li>",
"      You will need to wear compression boots (devices that go around the legs and inflate periodically) while you are lying down. Once you are able to get up and walk, you will wear anti-embolism stockings. These stockings fit snugly around the foot, ankle, lower leg, and knee to help prevent blood clots. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infection is another major concern, and you will be given antibiotics within an hour of the procedure and for up to 24 hours after.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;You will be encouraged to start moving your feet and ankles immediately after surgery. Some surgeons use a continuous passive motion device, which raises and slowly moves your leg while you are in bed. It is common to begin physical therapy one day after surgery, while you are still in the hospital.",
"   </p>",
"   <p>",
"    Physical therapy is an important part of the recovery process. After leaving the hospital, some people have physical therapy in their home or at a clinic, while others stay in a rehabilitation facility or nursing home for a few days.",
"   </p>",
"   <p>",
"    The rehabilitation program generally includes exercises to improve range of motion (how far you can bend and straighten your knee) and to strengthen your leg muscles. Your surgeon and physical therapist will help to set goals as you progress through rehabilitation.",
"   </p>",
"   <p>",
"    The goal of the rehabilitation period is to regain strength and movement in the knee; it is important to avoid overworking or straining the knee during this recovery period. You can usually resume your normal activities within three to six weeks after surgery. After several months of rehabilitation, you will be able to have a more active lifestyle. High-impact sports such as running and sports that involve heavy contact (football) are not recommended, but you should be able to participate in activities like walking, bicycling, and swimming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Potential complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications are not common after knee replacement. However, it is important to be aware of the major potential complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link\">",
"     \"Complications of total knee arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have shown that a successful joint replacement partially depends upon the experience of the surgeon and the hospital. In one study, outcomes were better in people who had:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A surgeon who performed more than six knee replacements each year",
"     </li>",
"     <li>",
"      Surgery performed in a hospital where more than 25 joint replacements were performed per year [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21717/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Better outcomes included better knee function and lower rates of complications after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Blood clot",
"    </span>",
"    &nbsp;&mdash;&nbsp;Having total knee replacement increases the risk of a blood clot forming in a vein (called a thrombosis). The most common place for a thrombosis to develop after knee surgery is in the deep veins of the leg (called a deep vein thrombosis). Symptoms of a DVT include leg pain and swelling. Call your doctor's office if you are worried that you could have a DVT. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"     \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection following knee replacement is a relatively uncommon but serious complication. Signs of infection include fever, chills, pain in the knee that gets worse suddenly, increasing redness, or swelling. Call your doctor's office if you are worried that you could have an infection.",
"   </p>",
"   <p>",
"    Wound infections are treated with antibiotics and occasionally by draining excess fluid from the joint. If an infection becomes deep or extensive, the prosthetic joint may need to be removed and reimplanted later, after the infection has cleared. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"     \"Patient information: Joint infection (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4447323\">",
"    <span class=\"h3\">",
"     Stiffness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, despite physical therapy, a patient&rsquo;s knee may get stiff and may not bend or straighten properly. If this occurs, then the patient may return to the operating room in order to bend",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    straighten the knee under anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4447330\">",
"    <span class=\"h3\">",
"     Early failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most studies demonstrate that 80 to 90 percent of total knees will last between 15 to 20 years, early failures may occur due to a variety of reasons. These include loosening of the implants, infection, fractures of the bone around the implants, and instability. When early failures occur, revision surgery may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804424308\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181960748\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=see_link\">",
"     Patient information: Knee replacement (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"     Patient information: Osteoarthritis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=see_link\">",
"     Patient information: Paget disease of bone (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181960807\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=see_link\">",
"     Patient information: Knee pain (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"     Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"     Patient information: Joint infection (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link\">",
"     Complications of total knee arthroplasty",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=see_link\">",
"     Low molecular weight heparin for venous thromboembolic disease",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"     Clinical manifestations and diagnosis of prosthetic joint infections",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link\">",
"     Prevention of prosthetic joint infections",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link\">",
"     Prevention of venous thromboembolic disease in medical patients",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     Prevention of venous thromboembolic disease in surgical patients",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     Surgical therapy of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=see_link\">",
"     Total joint replacement for severe rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=see_link\">",
"     Total knee arthroplasty",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     Treatment of prosthetic joint infections",
"    </a>",
"    <br/>",
"   </p>",
"   <p>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"       www.nlm.nih.gov/medlineplus/healthtopics.html",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Arthritis Foundation",
"      <br/>",
"      (800) 283-7800",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.arthritis.org/\">",
"       www.arthritis.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      American Academy of Orthopaedic Surgeons",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.aaos.org/\">",
"       www.aaos.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21717/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/1\">",
"      Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007; 89:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/2\">",
"      Reichenbach S, Rutjes AW, N&uuml;esch E, et al. Joint lavage for osteoarthritis of the knee. Cochrane Database Syst Rev 2010; :CD007320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/3\">",
"      Newman J, Pydisetty RV, Ackroyd C. Unicompartmental or total knee replacement: the 15-year results of a prospective randomised controlled trial. J Bone Joint Surg Br 2009; 91:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/4\">",
"      Katz JN, Mahomed NN, Baron JA, et al. Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older. Arthritis Rheum 2007; 56:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/5\">",
"      Rand JA, Trousdale RT, Ilstrup DM, Harmsen WS. Factors affecting the durability of primary total knee prostheses. J Bone Joint Surg Am 2003; 85-A:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/6\">",
"      Gill GS, Joshi AB. Long-term results of cemented, posterior cruciate ligament-retaining total knee arthroplasty in osteoarthritis. Am J Knee Surg 2001; 14:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/7\">",
"      Kirwan JR, Currey HL, Freeman MA, et al. Overall long-term impact of total hip and knee joint replacement surgery on patients with osteoarthritis and rheumatoid arthritis. Br J Rheumatol 1994; 33:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/8\">",
"      Bentley G, Minas T. Treating joint damage in young people. BMJ 2000; 320:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21717/abstract/9\">",
"      Brouwer RW, Jakma TS, Bierma-Zeinstra SM, et al. Osteotomy for treating knee osteoarthritis. Cochrane Database Syst Rev 2005; :CD004019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 704 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-118.97.94.19-E6249A1558-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21717=[""].join("\n");
var outline_f21_13_21717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REASONS FOR KNEE REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALTERNATIVES TO KNEE REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonsurgical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arthroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Osteotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Partial knee replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THE KNEE REPLACEMENT PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Potential complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Blood clot",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4447323\">",
"      - Stiffness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4447330\">",
"      - Early failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1804424308\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181960748\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181960807\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/704|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/11/17584\" title=\"figure 1\">",
"      Basic knee anatomy PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=related_link\">",
"      Complications of total knee arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=related_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=related_link\">",
"      Patient information: Knee replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=related_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=related_link\">",
"      Total knee arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_13_21718="Secobarbital: Pediatric drug information";
var content_f21_13_21718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Secobarbital: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/27/32182?source=see_link\">",
"    see \"Secobarbital: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/55/28532?source=see_link\">",
"    see \"Secobarbital: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Seconal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/27/32182?source=see_link\">",
"      see \"Secobarbital: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative sedation: 2-6 mg/kg (maximum dose: 100 mg/dose) 1-2 hours before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation: 6 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypnotic: Usual: 100 mg/dose at bedtime; range 100-200 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative sedation: 100-300 mg 1-2 hours before procedure",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Seconal&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F220213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of insomnia; preanesthetic agent",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Seconal&reg; may be confused with Sectral&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F220216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal thinking, agitation, angioedema, anxiety, apnea, ataxia, bradycardia, CNS depression, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls), confusion, constipation, dizziness, exfoliative dermatitis, fever, hallucinations, headache,  hyperkinesis, hypotension, hypoventilation, insomnia, liver injury, megaloblastic anemia, nausea, nervousness, nightmares, pain at injection site, rash, syncope, unusual excitement, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to secobarbital or any component; pre-existing CNS depression, severe uncontrolled pain, porphyria, severe respiratory disease with dyspnea or obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypovolemic shock, CHF, hepatic impairment, respiratory dysfunction or depression, previous addiction to the sedative/hypnotic group, chronic or acute pain, renal dysfunction; tolerance or psychological and physical dependence may occur with prolonged use; abrupt discontinuation after prolonged use may result in withdrawal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4805288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions including anaphylaxis and angioedema may occur. Hazardous sleep-related activities, such as sleep-driving (driving while not fully awake without any recollection of driving), preparing and eating food, and making phone calls while asleep have also been reported. Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F220207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP2A6 (strong), CYP2C8 (strong), CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inducers (Strong) may increase the metabolism of CYP2A6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High doses of pyridoxine may decrease drug effect; barbiturates may increase the metabolism of vitamins D and K",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10924210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates can be detected in the placenta, fetal liver, and fetal brain. Fetal and maternal blood concentrations may be similar following parenteral administration. An increased incidence of fetal abnormalities may occur following maternal use. When used during the third trimester of pregnancy, withdrawal symptoms may occur in the neonate including seizures and hyperirritability; symptoms may be delayed up to 14 days. Use during labor does not impair uterine activity; however, respiratory depression may occur in the newborn; resuscitation equipment should be available, especially for premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, respiratory rate, pulse oximetry, CNS status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses CNS activity by binding to barbiturate site at GABA-receptor complex enhancing GABA activity; depresses reticular activating system; higher doses may be gabamimetic",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1055404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hypnosis: Oral: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Hypnosis: Oral: 3-4 hours with 100 mg dose",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed (90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1.5 L/kg; crosses the placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 45% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver by the microsomal enzyme system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-13 years: 2.7-13.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 15-40 hours; mean 28 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renally as inactive metabolites and small amounts as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis: Slightly dialyzable (5% to 20%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/55/28532?source=see_link\">",
"      see \"Secobarbital: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol and other CNS depressants. May be habit-forming; avoid abrupt discontinuation after prolonged use. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May cause hypersensitivity reactions. May cause hazardous sleep-related activities (ie, driving, preparing and eating foods, and making phone calls while not fully awake).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Effectiveness for insomnia decreases greatly after 2 weeks of use; alkalinization of urine does not significantly increase excretion; withdraw slowly over 5-6 days after prolonged use to avoid sleep disturbances and rapid eye movement (REM) rebound",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In March 2007, the FDA requested that all manufacturers of sedative-hypnotic drug products, including Seconal&reg; (secobarbital), revise the labeling to include a greater emphasis on the risks of adverse events. The events include severe hypersensitivity reactions including anaphylaxis and/or angioedema, as well as hazardous sleep-related activities (eg, sleep-driving - driving while not fully awake after consumption of sedative-hypnotic drug, with no recollection of the event). Other activities may include preparing and ingesting food, and the use of the telephone, while asleep. These events may occur at any time during therapy including with the first dose administered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Manufacturers must provide written notification to healthcare providers regarding the new warnings. In addition, manufacturers are to develop &ldquo;Patient Medication Guides&rdquo; designed to educate consumers about the potential risks and to advise them of precautionary measures that can be taken. This advice will contain recommendations on correct utilization of the medication as well as the avoidance of the consumption of ethanol and/or other CNS-depressant agents. The FDA is also recommending manufacturers conduct studies evaluating the frequencies of sleep-driving (and other sleep-related behaviors) with the individual products.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients should be instructed not to discontinue these medications without first speaking with their healthcare provider. Patients should also be informed of the potential for an allergic reaction, the signs and symptoms of anaphylaxis, and the appropriate emergency self-treatment of an anaphylactic reaction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional information on the sedative-hypnotic products and sleep disorders is available at",
"     <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108868.htm%20\" target=\"_blank\">",
"      file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108868.htm",
"     </a>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Levine HL, Cohen ME, Duffner PK, et al, &ldquo;Rectal Absorption and Disposition of Secobarbital in Epileptic Children,&rdquo;",
"      <i>",
"       Pediatr Pharmacol (New York)",
"      </i>",
"      , 1982, 2(1):33-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21718/abstract-text/7110754/pubmed\" id=\"7110754\" target=\"_blank\">",
"        7110754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC, Starling S, and Edwards RC, &ldquo;Prolonged Sedation Associated With Secobarbital in Newborn Infants Receiving Ventilatory Support,&rdquo;",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 1991, 8(1):35-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21718/abstract-text/1987965 /pubmed\" id=\"1987965 \" target=\"_blank\">",
"        1987965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfert RR and Cox RM, &ldquo;Room Temperature Stability of Drug Products Labeled for Refrigerated Storage,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1975, 32(6):585-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21718/abstract-text/1155470 /pubmed\" id=\"1155470 \" target=\"_blank\">",
"        1155470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12783 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21718=[""].join("\n");
var outline_f21_13_21718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220193\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055398\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055392\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220172\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220157\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220213\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055402\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220218\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220216\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055406\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055391\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4805288\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220207\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220166\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055409\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220167\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10924210\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055397\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055390\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055404\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055405\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055396\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055407\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12783|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/27/32182?source=related_link\">",
"      Secobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/55/28532?source=related_link\">",
"      Secobarbital: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_13_21719="Drospirenone and estradiol: Drug information";
var content_f21_13_21719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Drospirenone and estradiol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/30/2534?source=see_link\">",
"    see \"Drospirenone and estradiol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1884104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Angeliq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Angeliq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1884108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1891115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Moderate-to-severe vasomotor symptoms associated with menopause:",
"     </b>",
"     Oral: Drospirenone 0.25 mg/estradiol 0.5 mg or drospirenone 0.5 mg/estradiol 1 mg per tablet: One tablet daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Atrophic vaginitis in females with an intact uterus:",
"     </b>",
"     Oral: Drospirenone 0.5 mg/estradiol 1 mg per tablet: One tablet daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The lowest dose of estrogen/progestin that will control symptoms should be used; medication should be discontinued as soon as possible. Patients should be re-evaluated periodically to see if treatment is still necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1891116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F1891117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F1891118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1891120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Angeliq&reg;: Drospirenone 0.25 mg and estradiol 0.5 mg; drospirenone 0.5 mg and estradiol 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1884106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14271118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be swallowed whole and taken at the same time each day. Bleeding may occur if several doses are missed. Women who are not taking estrogen or who are changing from a continuous combination product may start therapy at any time. Women who are switching from sequential or cyclic hormone therapy should complete the current cycle before switching to this product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1884109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of vulvar and vaginal atrophy associated with menopause",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14853758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral and transdermal patch]; Strength of recommendation - strong [oral and transdermal patch]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1884118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Breast pain (6% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Genital tract bleeding (3% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Emotional lability (1%), migraine (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal/GI pain  (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Cervical polyp (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Breast cancer, hypersensitivity reactions, venous and arterial thromboembolic events",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1884113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema or anaphylactic reaction drospirenone, estradiol, or any component of the formulation; undiagnosed abnormal vaginal bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast (known, suspected or history of); estrogen-dependent tumor; hepatic or renal dysfunction or disease; adrenal insufficiency; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1884114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Drospirenone has antimineralocorticoid activity that may lead to hyperkalemia. Use is contraindicated in patients with conditions which predispose to hyperkalemia (eg, renal insufficiency, hepatic dysfunction, or adrenal insufficiency); use caution with medications that may increase serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyponatremia: Drospirenone may increase the possibility of hyponatremia in high risk patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; discontinue if pancreatitis occurs. Use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chorea minor: Use caution with chorea minor; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroidism: Use caution in patients with hypoparathyroidism; estrogen-induced hypocalcemia may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Otosclerosis: Use caution with otosclerosis; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid oral and transdermal patch estrogen products (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premenopausal women: Not for use prior to menopause.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). Drospirenone can also cause an increase in plasma renin activity and plasma aldosterone. The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1884122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1884121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1884123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (routine use increases estrogen level and risk of breast cancer). Ethanol may also increase the risk of osteoporosis.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1884110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated during pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F1884111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1884112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following administration of an oral contraceptive agent containing drospirenone, ~0.02% of the dose was detected in breast milk, resulting in a maximum of ~3 mcg/day drospirenone to the infant.  Estrogens may decrease the quality and quantity of breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5164292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Angeliq Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-0.5 mg (28): $109.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-1 mg (28): $109.88",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1891119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yearly physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Menopausal symptoms: Assess need for therapy periodically",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Angeliq (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1891108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone is a synthetic progestin and spironolactone analog with antimineralocorticoid and antiandrogenic activity. Counteracts estrogen effects causing endometrial thinning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principal intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1884126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Drospirenone: 4.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Drospirenone: 97%; does not bind to sex hormone binding globulin or corticosteroid binding globulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Estradiol: 37% bound to sex hormone binding globulin; 61% bound to albumin",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Drospirenone forms two metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Estradiol: Converted to estrone and estriol; also undergoes enterohepatic recirculation; estrone sulfite is the main metabolite in postmenopausal women",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Drospirenone: 76% to 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Drospirenone: ~36-42 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Drospirenone: 1 hour; Estradiol: ~2 hours (range: 0.3-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Drospirenone: Urine and feces; Estradiol: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wassertheil-Smoller S, Hendrix S, Limacher M, et al, &ldquo;Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women's Health Initiative: A Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289:2673-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21719/abstract-text/12771114/pubmed\" id=\"12771114\" target=\"_blank\">",
"        12771114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8802 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21719=[""].join("\n");
var outline_f21_13_21719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708709\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884104\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935275\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884108\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891115\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891116\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891117\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891118\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891120\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884106\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14271118\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884109\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14853758\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884118\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884113\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884114\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884122\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884121\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884123\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884110\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884111\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884112\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5164292\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891119\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301368\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891108\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884126\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/30/2534?source=related_link\">",
"      Drospirenone and estradiol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_13_21720="Paragangliomas of the head and neck";
var content_f21_13_21720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paragangliomas of the head and neck",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21720/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21720/contributors\">",
"     Carl Snyderman, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21720/contributors\">",
"     Derrick Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21720/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21720/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21720/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21720/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/13/21720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paragangliomas are rare tumors that arise from widely dispersed specialized neural crest cells that are associated with autonomic ganglia (",
"    <a class=\"graphic graphic_figure graphicRef53140 \" href=\"UTD.htm?15/42/16046\">",
"     figure 1",
"    </a>",
"    ). These cells have the ability to secrete neuropeptides and catecholamines.",
"   </p>",
"   <p>",
"    Paragangliomas occur in four types of locations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Branchiomeric (jugulotympanic, carotid body, laryngeal, subclavian, and aorticopulmonary); paragangliomas arising in the carotid body are often referred to as chemodectomas [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intravagal (at the level of the jugular or nodose ganglion); jugulotympanic tumors are sometimes referred to as glomus jugulare tumors",
"     </li>",
"     <li>",
"      Aorticosympathetic",
"     </li>",
"     <li>",
"      Visceral autonomic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Paragangliomas arising in the head and neck region are discussed here. Those at other sites are discussed in conjunction with other tumors at those locations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid body tumors typically present as painless, gradually enlarging masses located in the upper part of the neck below the angle of the jaw [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/4\">",
"     4",
"    </a>",
"    ]. Hoarseness and Horner's syndrome may result from pressure on the vagus or sympathetic nerves. Jugulotympanic and vagal paragangliomas present with pulsatile tinnitus, dizziness, blurred vision, facial droop, neck masses, or pain.",
"   </p>",
"   <p>",
"    Carotid body tumors are the most common paragangliomas of the head and neck region (60 percent), followed by jugulotympanic and vagal paragangliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/5-11\">",
"     5-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inherited paragangliomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paragangliomas are a component of an inherited syndrome in 10 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Inherited disease is approximately six times more likely among patients with a carotid body tumor than in those with paraganglioma at other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=see_link\">",
"     \"Pheochromocytoma in genetic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four hereditary paraganglioma syndromes have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/12,14-16\">",
"     12,14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraganglioma syndrome 1 is associated with mutations in the succinate dehydrogenase (SDH) complex subunit D.",
"     </li>",
"     <li>",
"      Paraganglioma syndrome 4 is associated with mutations in the succinate dehydrogenase (SDH) complex subunit B.",
"     </li>",
"     <li>",
"      Paraganglioma syndrome 3 is associated with mutations in the succinate dehydrogenase (SDH) complex subunits C.",
"     </li>",
"     <li>",
"      In the paraganglioma syndrome 2, a specific mutation has not been identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a registry that included 63 patients with identified mutations, SDH D mutations were the most common, occurring in 71 percent of cases. SDH B and C mutations accounted for 21 and 8 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inherited versus sporadic paraganglioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several important differences in the clinical manifestations of familial and sporadic paragangliomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hereditary paragangliomas tend to develop disease at a younger age than those with sporadic paragangliomas. For patients with SDH D and B mutations, 50 percent present by ages 31 and 35, respectively, and over three-quarters of patients will present by age 50 in both of these syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one series of hereditary paragangliomas, disease was only slightly more common among women (54 versus 46 percent in men), while sporadic tumors were much more common in women (71 versus 29 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malignant paragangliomas are more common in patients with SDH B mutations than in those with other mutations or with sporadic disease. In a series of 195 patients analyzed for mutations, metastatic bone disease was present in 7 of 13 patients with SDH B mutations. In contrast, none of the 68 patients with SDH D or C mutations had metastases, and only 1 of 132 patients (0.8 percent) with sporadic disease had a metastasis, which was limited to a cervical lymph node [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple paragangliomas are present in 70 to 87 percent of inherited cases compared to 10 percent or less in sporadic cases [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/10,18,19\">",
"       10,18,19",
"      </a>",
"      ]. In addition, paragangliomas may be associated with pheochromocytomas or other multiple endocrine neoplasia type 2 (MEN2)-associated tumors.",
"     </li>",
"     <li>",
"      Mutations in SDH complex have been identified in some patients who present with apparently sporadic pheochromocytomas (ie, with no family history or other tumors), suggesting an inherited condition and a higher risk for multiple tumors. In a review of 271 such patients, 23 (8 percent) had an SDH B or D mutation, four of whom subsequently developed glomus tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/17\">",
"       17",
"      </a>",
"      ]. In another series of 417 patients with pheochromocytomas or head and neck paragangliomas without features suggesting and inherited syndrome, head and neck paragangliomas and multifocal tumors were more frequent among patients with SDH D mutations (PGL1) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"       \"Clinical presentation and diagnosis of pheochromocytoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"       \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of screening for SDH mutations is still controversial. We offer genetic screening to our patients with paragangliomas, although it is not mandatory in such patients.",
"   </p>",
"   <p>",
"    For those in whom SDH B mutations are identified, further evaluation for disseminated disease is indicated to exclude metastatic disease. For patients with any of the SDH mutations, appropriate genetic counseling of the patient and first degree relatives should be offered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=see_link&amp;anchor=H5#H5\">",
"     \"Pheochromocytoma in genetic disorders\", section on 'Familial paraganglioma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Functioning paragangliomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor production of vasoactive catecholamines by paragangliomas may lead to hypertension and other symptoms of catecholamine excess, such as headaches, palpitation, and sweating, nervousness, and weight loss. As an example, in one series of 236 patients with paragangliomas at any location, catecholamine hypersecretion was found in 40 of 128 screened patients (31 percent) and 38 were hypertensive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/10\">",
"     10",
"    </a>",
"    ]. However, functional hormone secretion is less common with head and neck paragangliomas, occurring in only 1 to 3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/11,21\">",
"     11,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough work-up should be carried out prior to defining a treatment plan. Several staging systems have been proposed for carotid body tumors and jugulotympanic paragangliomas, although none have been widely adopted [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Few studies report their results based upon any staging system, making it difficult to compare results between studies. The",
"    <span class=\"nowrap\">",
"     McCabe/Fletcher",
"    </span>",
"    staging system is based upon older studies such as plain radiographs and retrograde jugulography, and as a result, the Fisch and",
"    <span class=\"nowrap\">",
"     Glasscock/Jackson",
"    </span>",
"    systems are currently preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CT and Doppler ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation usually includes CT of the neck and chest. The classic findings include a homogeneous mass with intense enhancement following administration of intravenous contrast.",
"   </p>",
"   <p>",
"    Tumor location, displacement of major vessels, and patterns of involvement of invasion of surrounding structures may permit the distinction between carotid body and vagal or jugulotympanic paragangliomas by CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Doppler sonography [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid body tumors typically displace the common carotid bifurcation with posterolateral displacement of the internal carotid artery [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vagal paragangliomas displace both the internal and external carotid arteries anteriorly and are associated with erosion and widening of the jugular foramen.",
"     </li>",
"     <li>",
"      Jugular paragangliomas may be distinguished from tympanic tumors based upon early involvement of the skull base, erosion of the spine, and destruction of the ossicular chain, which is unusual for tympanic tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/27-29\">",
"       27-29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although CT is the procedure of choice for evaluation of bone involvement, gadolinium-enhanced MRI provides superior definition of the relationship of paragangliomas to adjacent vascular and skull base structures. On T1-weighted magnetic resonance images, paragangliomas typically have a background tumor matrix of intermediate signal density, with scattered areas of signal void, reflecting high-flow blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/11\">",
"     11",
"    </a>",
"    ]. Intense homogeneous contrast enhancement is seen. On T2-weighted images, the classic \"salt and pepper\" appearance is present in most lesions larger than 1.5 cm, reflecting signal voids intermixed with regions of focally intense signal intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/11,30\">",
"     11,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These MRI findings are not specific for paragangliomas and may be seen with other hypervascular tumors (eg, metastatic renal cell or thyroid carcinoma). However, the typically smooth contour, signal characteristics, and location of paragangliomas coupled with the history and physical examination should enable the correct diagnosis to be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radioisotope imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paragangliomas, like many other neuroendocrine tumors, have a high density of somatostatin type 2 receptors on their cell surface and can be imaged using somatostatin receptor scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. One study evaluated preoperative scintigraphy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    in 21 patients undergoing surgery for presumed head and neck paragangliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/33\">",
"     33",
"    </a>",
"    ]. Scans were positive in 16 patients with paragangliomas and negative in three with other pathology. The overall test accuracy was 90 percent, and the sensitivity and specificity were 94 and 75 percent, respectively. Preoperative somatostatin receptor scintigraphy can sometimes identify unexpected foci of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective arteriography plays an important role in the evaluation of paragangliomas if surgery is being considered. Although tumor extent is often well demonstrated by CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI, its vascularity is best studied with digital subtraction angiography, which is superior to MR angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition to demonstrating displacement of blood vessels, potential vessel compromise by tumor invasion, and the adequacy of the intracranial circulation if internal carotid artery sacrifice is necessary, angiography can also reveal previously unsuspected synchronous paragangliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum and urine catecholamine levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24-hour urine for catecholamines and metanephrines is appropriate if a functioning tumor is suspected. Serum catecholamine levels are also of value. Because paragangliomas do not secrete epinephrine, an elevated serum epinephrine level suggests a concurrent pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a paraganglioma is usually based upon imaging findings. Biopsy (either incisional or fine needle aspirate) is relatively contraindicated when the diagnosis is suspected, due to the risk of hemorrhage or subsequent fibrosis at the operative site [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grossly, paragangliomas have a fleshy, red brown to gray appearance due to hemorrhage or fibrosis. Paragangliomas are highly vascular and typically are associated with blood vessels (carotid artery, jugular bulb) and neural structures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, paragangliomas have a thin capsule and are composed of round or polygonal epithelioid cells arranged in compact cell nests (Zellballen) or trabecular patterns (",
"    <a class=\"graphic graphic_picture graphicRef76309 \" href=\"UTD.htm?30/12/30920\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/5,6,35,36\">",
"     5,6,35,36",
"    </a>",
"    ]. Spindle shaped sustentacular or supporting cells are found peripheral to the chief cell nests. The chief cells have centrally located nuclei with finely clumped chromatin, and a moderate amount of eosinophilic, granular cytoplasm. Tumors of higher grade are characterized by a progressive loss in the relationship between chief cells and sustentacular cells, and a decrease in the overall number of sustentacular cells.",
"   </p>",
"   <p>",
"    Paragangliomas may be mistaken histologically for a variety of tumors, including meningioma, nerve sheath tumor, hemangiopericytoma, adult rhabdomyoma, melanoma, sarcoma, and metastatic carcinoma. Immunohistochemical staining typically confirms the neuroendocrine nature of the chief cells with diffuse, strong positivity for neuron-specific enolase (NSE), synaptophysin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chromogranin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Ultrastructurally, chief cells contain dense core neurosecretory granules (100 to 200 nm), which are the sites of catecholamine storage. Sustentacular cells are negative for neuroendocrine markers but may be S-100 or GFAP positive.",
"   </p>",
"   <p>",
"    Histology alone cannot reliably differentiate benign from malignant tumors. Nuclear pleomorphism, necrosis, mitoses, and local invasion may be seen in benign paragangliomas and they are not diagnostic of malignancy. Metastases are required to establish a diagnosis of malignancy. Although DNA ploidy is abnormal in the majority of carotid body tumors and vagal paragangliomas, it is of limited value in predicting prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, less than 10 percent of paragangliomas are malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Malignancy is least common for jugulotympanic tumors (2 to 4 percent), approximately 6 percent for carotid body tumors, and highest for vagal tumors (16 to 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/37\">",
"     37",
"    </a>",
"    ]. Malignancy is particularly common in tumors associated with SDH B mutations. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Inherited versus sporadic paraganglioma'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a wide spectrum of clinical behavior for paragangliomas of the head and neck region. The variable growth rate of these tumors is an important consideration in determining whether to intervene therapeutically.",
"   </p>",
"   <p>",
"    The potentially indolent nature of these tumors is illustrated by a retrospective analysis of 48 patients who were followed without active treatment for an average of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/39\">",
"     39",
"    </a>",
"    ]. The median growth rate was 1.0 mm annually (range 0.3 to 5 mm per year), and the median tumor doubling time was four years (range 0.6 to 21.5 years). Seventy-five percent of tumors 0.8 to 4.5 cm in diameter showed active growth. In contrast, less than one-half of lesions either smaller than 0.8 cm or larger than 4.5 cm in diameter grew during the period of observation. Similar results have been seen in other series of carefully selected patients followed without immediate intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, observation should be considered in patients with small or moderate-sized asymptomatic paragangliomas that can be closely monitored to assess the natural history in an individual patient.",
"   </p>",
"   <p>",
"    Historically, surgical resection was the treatment of choice. Increasing data indicate that radiation therapy (external beam, stereotactic radiosurgery, or stereotactic radiotherapy) may offer comparable results. Radiation therapy (RT) is associated with a decrease in acute, treatment-related toxicity. However, the follow-up with these approaches is relatively short and there are no randomized trials that compare RT to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery can provide long-term local control for patients with head and neck paragangliomas.",
"   </p>",
"   <p>",
"    Important considerations for patients who will undergo surgical resection include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paragangliomas have a rich blood supply. Preoperative embolization of the tumor's main arterial supply may help to reduce bleeding and other complications associated with removal of large tumors, thus facilitating resection [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with catecholamine-secreting paragangliomas require appropriate medical preparation for surgery. The anesthesiologist must be prepared to counteract alpha- and beta-adrenergic catecholamine-induced cardiovascular effects when dealing with functioning tumors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link\">",
"       \"Treatment of pheochromocytoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although the risk of metastatic disease is small, all enlarged ipsilateral lymph nodes should be removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because head and neck paragangliomas are anatomically close to a number of critical structures, surgical resection can be complicated by a variety of major complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/4,43-45\">",
"     4,43-45",
"    </a>",
"    ]. The likelihood of a serious complication varies depending upon the size and location of the tumor. As an example, in a retrospective, multicenter series of 95 patients treated over a 26-year period, surgery was complicated by stroke, bleeding, or cranial nerve injury in 1, 6, and 18 patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/4\">",
"     4",
"    </a>",
"    ]. Resection of bilateral carotid body tumors may cause the baroreflex failure syndrome, which is characterized by severe, constant hypertension in the first 24 to 72 hours after surgery followed by labile hypertension and hypotension, headaches, emotional instability, and palpitations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term follow-up is important following resection. A significant proportion of patients with apparently benign paragangliomas will have persistent or recurrent disease or develop metachronous primary paragangliomas. In one series of 236 patients with benign paragangliomas, persistent, recurrent, or metachronous disease was found in 3, 12, and 8 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/10\">",
"     10",
"    </a>",
"    ]. The interval between treatment of a primary tumor and appearance of a recurrence or metastasis may be long, with some recurrences reported up to 20 years after the initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/11,48\">",
"     11,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) appears to be an effective alternative to surgery for improving symptoms and achieving local control in certain patients with paraganglioma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Conventional external beam RT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/43,48,49\">",
"     43,48,49",
"    </a>",
"    ], stereotactic radiation therapy (SRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], and stereotactic radiation surgery (SRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/53\">",
"     53",
"    </a>",
"    ] have all been used successfully. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results with RT are illustrated by two large series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single institution series of 121 paragangliomas managed with RT, the ten-year local control rate was 95 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/48\">",
"       48",
"      </a>",
"      ]. In this series, 74 percent were treated with conventional external beam, and the remainder with stereotactic or intensity modulated techniques.",
"     </li>",
"     <li>",
"      A review of the literature of small series treated with SRS found that local control was achieved in 125 of 131 patients (95 percent), and symptoms were controlled in 127 (97 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Adjuvant radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who undergo resection of malignant paragangliomas may benefit from adjuvant RT. There are no prospective trials specifically evaluating the benefit of postoperative RT in such patients, and observational studies are subject to selection bias. However, in a series of 59 cases of malignant paraganglioma of the head and neck extracted from the National Cancer Data Base, patients treated with surgery and RT had a superior median survival compared to those managed with surgery alone (45 versus 12 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only very limited data on the responsiveness of paragangliomas to chemotherapy. Most literature reports evaluating cytotoxic chemotherapy for progressive metastatic paragangliomas predominantly involve patients with retroperitoneal functioning tumors.",
"   </p>",
"   <p>",
"    Malignant paragangliomas appear to be sensitive to cytotoxic chemotherapy, although the optimal regimen has not been identified. The most extensive data are from studies using various combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. The following illustrates the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II study, 18 patients with metastatic malignant",
"      <span class=\"nowrap\">",
"       pheochromocytoma/paraganglioma",
"      </span>",
"      were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (CVD regimen) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/55\">",
"       55",
"      </a>",
"      ]. The overall response rate was 55 percent, and a biochemical response occurred in 72 percent. The median duration of response was 20 months, and at a median follow-up of 22 years, the median survival duration was 3.3 years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of pheochromocytoma in adults\", section on 'Malignant pheochromocytoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a second retrospective series, 11 patients received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (CyADIC), cyclophosphamide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , doxorubicin, and dacarbazine (CyVADIC), or doxorubicin and dacarbazine (ADIC) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/54\">",
"       54",
"      </a>",
"      ]. Six of 13 patients (46 percent) achieved an objective partial remission.",
"     </li>",
"     <li>",
"      Single case reports suggest that these tumors may also respond to single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      with [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/57\">",
"       57",
"      </a>",
"      ] and without [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/58\">",
"       58",
"      </a>",
"      ]&nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , or the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"       streptozocin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metaiodobenzylguanidine (MIBG), a radionuclide that is usually used as a diagnostic agent in catecholamine-producing tumors arising from chromaffin tissue, may also be used therapeutically in patients with advanced paragangliomas. In advanced paraganglioma, 131I-MIBG may allow symptom palliation and tumor regression or stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    has also been reported to produce an objective response in advanced malignant paragangliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21720/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with small (&lt;3 cm), asymptomatic paragangliomas of the head and neck, we suggest a period of observation to monitor for evidence of tumor growth or the development of symptoms rather than immediate treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Primary tumor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical resection and radiation therapy (conventional external beam, stereotactic radiosurgery, or stereotactic radiotherapy) are appropriate options for patients with larger lesions and for those who are symptomatic. There are no randomized trials that compare these modalities, and the choice of therapy needs to consider the patient's overall condition, potential side effects, and availability of expertise for treatment. Either radiation therapy or surgery can provide local disease control in most patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most extensive data and the longest follow-ups are available for patients treated with surgical resection. The critical anatomic location and vascularity of these tumors make surgical complex and there is a significant risk of serious complications. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stereotactic radiosurgery is generally limited to patients with small lesions (&lt;3 cm). Stereotactic radiotherapy permits the treatment of larger lesions, but requires a more protracted course of therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with metastatic disease, we suggest systemic chemotherapy with a regimen such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Observational data suggest that this approach can palliate symptoms, although the effect on survival is uncertain. The radionuclide 131I metaiodobenzylguanidine may be another alternative. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tumors of the extra-adrenal paraganglion system (including chemoreceptors. In: Atlas of Tumor Pathology, Armed Forces Institute of Pathology, fascicle 9, second series, 1974.",
"    </li>",
"    <li>",
"     Paraganglioma. In: World Health Organization Classification of Tumours of the Nervous System, IARC Press, Lyon, France 2000. p.112.",
"    </li>",
"    <li>",
"     Carotid Body Paragangliomas. In: Pathology and Genetics of Head and Neck Tumors, IARC, 2005. p.364.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/4\">",
"      Sajid MS, Hamilton G, Baker DM, Joint Vascular Research Group. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg 2007; 34:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/5\">",
"      Persky MS, Setton A, Niimi Y, et al. Combined endovascular and surgical treatment of head and neck paragangliomas--a team approach. Head Neck 2002; 24:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/6\">",
"      Barnes L, Taylor SR. Carotid body paragangliomas. A clinicopathologic and DNA analysis of 13 tumors. Arch Otolaryngol Head Neck Surg 1990; 116:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/7\">",
"      Barnes L, Taylor SR. Vagal paragangliomas: a clinical, pathological, and DNA assessment. Clin Otolaryngol Allied Sci 1991; 16:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/8\">",
"      Eriksen C, Girdhar-Gopal H, Lowry LD. Vagal paragangliomas: a report of nine cases. Am J Otolaryngol 1991; 12:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/9\">",
"      Moore G, Yarington CT Jr, Mangham CA Jr. Vagal body tumors: diagnosis and treatment. Laryngoscope 1986; 96:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/10\">",
"      Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001; 86:5210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/11\">",
"      Hu K, Persky MS. Multidisciplinary management of paragangliomas of the head and neck, Part 1. Oncology (Williston Park) 2003; 17:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/12\">",
"      Boedeker CC, Neumann HP, Maier W, et al. Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg 2007; 137:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/13\">",
"      Drovdlic CM, Myers EN, Peters JA, et al. Proportion of heritable paraganglioma cases and associated clinical characteristics. Laryngoscope 2001; 111:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/14\">",
"      Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/15\">",
"      Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/16\">",
"      Niemann S, M&uuml;ller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/17\">",
"      Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/18\">",
"      Netterville JL, Jackson CG, Miller FR, et al. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg 1998; 124:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/19\">",
"      Netterville JL, Reilly KM, Robertson D, et al. Carotid body tumors: a review of 30 patients with 46 tumors. Laryngoscope 1995; 105:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/20\">",
"      Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/21\">",
"      Schwaber MK, Glasscock ME, Nissen AJ, et al. Diagnosis and management of catecholamine secreting glomus tumors. Laryngoscope 1984; 94:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/22\">",
"      Shamblin WR, ReMine WH, Sheps SG, Harrison EG Jr. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg 1971; 122:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/23\">",
"      McCabe BF, Fletcher M. Selection of therapy of glomus jugulare tumors. Arch Otolaryngol 1969; 89:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/24\">",
"      Jackson CG, Glasscock ME 3rd, Harris PF. Glomus Tumors. Diagnosis, classification, and management of large lesions. Arch Otolaryngol 1982; 108:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/25\">",
"      Oldring D, Fisch U. Glomus tumors of the temporal region: surgical therapy. Am J Otol 1979; 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/26\">",
"      Stoeckli SJ, Schuknecht B, Alkadhi H, Fisch U. Evaluation of paragangliomas presenting as a cervical mass on color-coded Doppler sonography. Laryngoscope 2002; 112:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/27\">",
"      Rao AB, Koeller KK, Adair CF. From the archives of the AFIP. Paragangliomas of the head and neck: radiologic-pathologic correlation. Armed Forces Institute of Pathology. Radiographics 1999; 19:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/28\">",
"      Cheng A, Niparko JK. Imaging quiz case 2. Glomus tympanicum tumor of the temporal bone. Arch Otolaryngol Head Neck Surg 1997; 123:549, 551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/29\">",
"      Swartz JD, Harnsberger HR, Mukherji SK. The temporal bone. Contemporary diagnostic dilemmas. Radiol Clin North Am 1998; 36:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/30\">",
"      Olsen WL, Dillon WP, Kelly WM, et al. MR imaging of paragangliomas. AJR Am J Roentgenol 1987; 148:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/31\">",
"      Telischi FF, Bustillo A, Whiteman ML, et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg 2000; 122:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/32\">",
"      Duet M, Sauvaget E, P&eacute;telle B, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 2003; 44:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/33\">",
"      Bustillo A, Telischi F, Weed D, et al. Octreotide scintigraphy in the head and neck. Laryngoscope 2004; 114:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/34\">",
"      van den Berg R, Wasser MN, van Gils AP, et al. Vascularization of head and neck paragangliomas: comparison of three MR angiographic techniques with digital subtraction angiography. AJNR Am J Neuroradiol 2000; 21:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/35\">",
"      Kliewer KE, Wen DR, Cancilla PA, Cochran AJ. Paragangliomas: assessment of prognosis by histologic, immunohistochemical, and ultrastructural techniques. Hum Pathol 1989; 20:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/36\">",
"      Kliewer KE, Cochran AJ. A review of the histology, ultrastructure, immunohistology, and molecular biology of extra-adrenal paragangliomas. Arch Pathol Lab Med 1989; 113:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/37\">",
"      Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer 2002; 94:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/38\">",
"      Manolidis S, Shohet JA, Jackson CG, Glasscock ME 3rd. Malignant glomus tumors. Laryngoscope 1999; 109:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/39\">",
"      Jansen JC, van den Berg R, Kuiper A, et al. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 2000; 88:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/40\">",
"      Langerman A, Athavale SM, Rangarajan SV, et al. Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg 2012; 138:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/41\">",
"      Wang SJ, Wang MB, Barauskas TM, Calcaterra TC. Surgical management of carotid body tumors. Otolaryngol Head Neck Surg 2000; 123:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/42\">",
"      Saringer W, Kitz K, Czerny C, et al. Paragangliomas of the temporal bone: results of different treatment modalities in 53 patients. Acta Neurochir (Wien) 2002; 144:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/43\">",
"      Huy PT, Kania R, Duet M, et al. Evolving concepts in the management of jugular paraganglioma: a comparison of radiotherapy and surgery in 88 cases. Skull Base 2009; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/44\">",
"      Papaspyrou K, Mann WJ, Amedee RG. Management of head and neck paragangliomas: review of 120 patients. Head Neck 2009; 31:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/45\">",
"      Makeieff M, Raingeard I, Alric P, et al. Surgical management of carotid body tumors. Ann Surg Oncol 2008; 15:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/46\">",
"      Chan WS, Wei WI, Tse HF. \"Malignant\" baroreflex failure after surgical resection of carotid body tumor. Int J Cardiol 2007; 118:e81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/47\">",
"      Maturo S, Brennan J. Baroreflex failure: a rare complication of carotid paraganglioma surgery. Laryngoscope 2006; 116:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/48\">",
"      Hinerman RW, Amdur RJ, Morris CG, et al. Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. Head Neck 2008; 30:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/49\">",
"      Chino JP, Sampson JH, Tucci DL, et al. Paraganglioma of the head and neck: long-term local control with radiotherapy. Am J Clin Oncol 2009; 32:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/50\">",
"      Krych AJ, Foote RL, Brown PD, et al. Long-term results of irradiation for paraganglioma. Int J Radiat Oncol Biol Phys 2006; 65:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/51\">",
"      Henzel M, Hamm K, Gross MW, et al. Fractionated stereotactic radiotherapy of glomus jugulare tumors. Local control, toxicity, symptomatology, and quality of life. Strahlenther Onkol 2007; 183:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/52\">",
"      Wegner RE, Rodriguez KD, Heron DE, et al. Linac-based stereotactic body radiation therapy for treatment of glomus jugulare tumors. Radiother Oncol 2010; 97:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/53\">",
"      Guss ZD, Batra S, Li G, et al. Radiosurgery for glomus jugulare: history and recent progress. Neurosurg Focus 2009; 27:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/54\">",
"      Patel SR, Winchester DJ, Benjamin RS. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 1995; 76:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/55\">",
"      Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008; 113:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/56\">",
"      Edstr&ouml;m Elder E, Hjelm Skog AL, H&ouml;&ouml;g A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 2003; 29:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/57\">",
"      Mora J, Cruz O, Parareda A, et al. Treatment of disseminated paraganglioma with gemcitabine and docetaxel. Pediatr Blood Cancer 2009; 53:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/58\">",
"      Pipas JM, Krywicki RF. Treatment of progressive metastatic glomus jugulare tumor (paraganglioma) with gemcitabine. Neuro Oncol 2000; 2:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/59\">",
"      Chow SN, Seear M, Anderson R, Magee F. Multiple pulmonary chemodectomas in a child: results of four different therapeutic regimens. J Pediatr Hematol Oncol 1998; 20:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/60\">",
"      Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008; 35:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21720/abstract/61\">",
"      Tenenbaum F, Schlumberger M, Lumbroso J, Parmentier C. Beneficial effects of octreotide in a patient with a metastatic paraganglioma. Eur J Cancer 1996; 32A:737.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5231 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21720=[""].join("\n");
var outline_f21_13_21720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inherited paragangliomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inherited versus sporadic paraganglioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Functioning paragangliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CT and Doppler ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radioisotope imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum and urine catecholamine levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Adjuvant radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5231|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/42/16046\" title=\"figure 1\">",
"      Neural crest and embryogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5231|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/12/30920\" title=\"picture 1\">",
"      Paraganglioma Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=related_link\">",
"      Pheochromocytoma in genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_13_21721="Sotalol: Drug information";
var content_f21_13_21721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sotalol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/22/33125?source=see_link\">",
"    see \"Sotalol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=see_link\">",
"    see \"Sotalol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betapace AF&reg;;",
"     </li>",
"     <li>",
"      Betapace&reg;;",
"     </li>",
"     <li>",
"      Sorine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sotalol&reg;;",
"     </li>",
"     <li>",
"      CO Sotalol;",
"     </li>",
"     <li>",
"      Dom-Sotalol;",
"     </li>",
"     <li>",
"      Med-Sotalol;",
"     </li>",
"     <li>",
"      Mylan-Sotalol;",
"     </li>",
"     <li>",
"      Novo-Sotalol;",
"     </li>",
"     <li>",
"      Nu-Sotalol;",
"     </li>",
"     <li>",
"      PHL-Sotalol;",
"     </li>",
"     <li>",
"      PMS-Sotalol;",
"     </li>",
"     <li>",
"      PRO-Sotalol;",
"     </li>",
"     <li>",
"      ratio-Sotalol;",
"     </li>",
"     <li>",
"      Rhoxal-sotalol;",
"     </li>",
"     <li>",
"      Riva-Sotalol;",
"     </li>",
"     <li>",
"      Rylosol;",
"     </li>",
"     <li>",
"      Sandoz-Sotalol;",
"     </li>",
"     <li>",
"      ZYM-Sotalol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F222538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class II;",
"     </li>",
"     <li>",
"      Antiarrhythmic Agent, Class III;",
"     </li>",
"     <li>",
"      Beta-Blocker, Nonselective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F222502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and creatinine clearance must be determined prior to initiation. Sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. Proarrhythmic events can occur after initiation of therapy and with each upward dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conversion from oral sotalol to I.V. sotalol:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:0em;text-align:justify;\">",
"     80 mg oral equivalent to 75 mg I.V.",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:0em;text-align:justify;\">",
"     120 mg oral equivalent to 112.5 mg I.V.",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:0em;text-align:justify;\">",
"     160 mg oral equivalent to 150 mg I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Ventricular arrhythmias:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     The effects of the initial I.V. dose must be monitored and the dose titrated either upward or downward, if needed, based on clinical effect, QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, or adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Substitution for oral sotalol: Initial dose: 75 mg infused over 5 hours twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Dose adjustment:",
"     </i>",
"     If the frequency of relapse does not reduce and excessive QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation does not occur, may increase to 112.5 mg twice daily. For ventricular arrhythmias, may increase dose every 3 days in increments of 75 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Dose range:",
"     </i>",
"     Usual therapeutic dose: 75-150 mg twice daily; maximum dose: 300 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodynamically stable monomorphic VT, ongoing (unlabeled use): 1.5 mg/kg over 5 minutes (ACLS, 2010);",
"     <b>",
"      Note:",
"     </b>",
"     Clinical trial employed standard dose of 100 mg (Ho, 1994).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral (Betapace&reg;, Sorine&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     80 mg twice daily; dose may be increased gradually to 240-320 mg/day; allow 3 days between dosing increments (to attain steady-state plasma concentrations and to allow monitoring of QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Usual range:",
"     </i>",
"     Most patients respond to 160-320 mg/day in 2-3 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maximum:",
"     </i>",
"     Some patients, with life-threatening refractory ventricular arrhythmias, may require doses as high as 480-640 mg/day; prescribed ONLY when the potential benefit outweighs the increased of adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation or atrial flutter:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     The effects of the initial I.V. dose must be monitored and the dose titrated either upward or downward, if needed, based on clinical effect, QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, or adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Substitution for oral sotalol: Initial dose: 75 mg infused over 5 hours twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Dose adjustment:",
"     </i>",
"     If the frequency of relapse does not reduce and excessive QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation does not occur, may increase to 112.5 mg twice daily. For ventricular arrhythmias, may increase dose every 3 days in increments of 75 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Dose range:",
"     </i>",
"     Usual therapeutic dose: 112.5 mg twice daily; maximum dose: 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral (Betapace AF&reg;): Initial: 80 mg twice daily. If the frequency of relapse does not reduce and excessive QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation does not occur after 3 days, the dose may be increased to 120 mg twice daily; may further increase to 160 mg twice daily if response is inadequate and QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation is not excessive.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F222521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=see_link\">",
"      see \"Sotalol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and creatinine clearance must be determined prior to initiation. Sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. Proarrhythmic events can occur after initiation of therapy and with each upward dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The safety and efficacy of sotalol in children have not been established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Supraventricular arrhythmias:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosing per manufacturer, based on pediatric pharmacokinetic data; wait at least 36 hours between dosage adjustments to allow monitoring of QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &le;2 years:",
"     </i>",
"     Dosage should be adjusted (decreased) by plotting of the child's age on a logarithmic scale; see graph or refer to manufacturer's package labeling.",
"    </p>",
"    (",
"    <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/57/41880\">",
"     See Age nomogram",
"    </a>",
"    )",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &gt;2 years:",
"     </i>",
"     Initial: 90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 3 divided doses; may be incrementally increased to a maximum of 180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F222503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F222504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Impaired renal function can increase the terminal half-life, resulting in increased drug accumulation. Sotalol (Betapace AF&reg;, injectable formulation) is contraindicated per the manufacturers for treatment of atrial fibrillation/flutter in patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ventricular arrhythmias (Betapace&reg;, Sorine&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Administer every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: Administer every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: Administer every 36-48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Individualize dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atrial fibrillation/flutter (Betapace AF&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Administer every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-60 mL/minute: Administer every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer of the injectable formulation recommends adjustment similar to that used for Betapace AF&reg;. However, the injectable formulation may be used for either indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis would be expected to reduce sotalol plasma concentrations because sotalol is not bound to plasma proteins and does not undergo extensive metabolism. Administer dose postdialysis or administer supplemental 80 mg dose. Peritoneal dialysis does not remove sotalol; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9830566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &ge;500 msec during initiation period:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Betapace AF&reg;: Reduce dose or discontinue sotalol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Injectable formulation: Reduce dose, decrease infusion rate, or discontinue sotalol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &ge;520 msec (or JT interval &ge;430 msec if the QRS &gt;100 msec) during maintenance therapy (Betapace AF&reg;, injectable formulation): Reduce dose and carefully monitor QT",
"     <sub>",
"      c",
"     </sub>",
"     until &lt;520 msec. If QT",
"     <sub>",
"      c",
"     </sub>",
"     interval &ge;520 msec on the lowest maintenance dose, discontinue sotalol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &ge;550 msec (Betapace&reg;, Sorine&reg;): Reduce dose or discontinue sotalol.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 15 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 80 mg [atrial fibrillation], 80 mg, 120 mg [atrial fibrillation], 120 mg, 160 mg [atrial fibrillation], 160 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betapace AF&reg;: 80 mg, 120 mg, 160 mg [scored; atrial fibrillation]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betapace&reg;: 80 mg, 120 mg, 160 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sorine&reg;: 80 mg, 120 mg, 160 mg, 240 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F222472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Substitution for oral: Administer over 5 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodynamically stable monomorphic VT: Administer I.V. push over 5 minutes; use with caution due to increased risk of adverse events (eg, bradycardia, hypotension, torsade de pointes) (ACLS, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9830565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or lactated Ringer's.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F222471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of documented ventricular arrhythmias (ie, sustained ventricular tachycardia), that in the judgment of the physician are life-threatening; maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation and atrial flutter who are currently in sinus rhythm. Manufacturer states substitutions should not be made for Betapace AF&reg; since Betapace AF&reg; is distributed with a patient package insert specific for atrial fibrillation/flutter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection: Substitution for oral sotalol in those who are unable to take sotalol orally",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9830364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal tachycardia; alternative antiarrhythmic for the treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy (HCM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F222546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sotalol may be confused with Stadol, Sudafed&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Betapace&reg; may be confused with Betapace AF&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F222536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     No clinical experience with I.V. sotalol; however, since exposure is similar between I.V. and oral sotalol, adverse reactions are expected to be similar.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (13% to 16%), chest pain (3% to 16%), palpitation (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (20%), dizziness (20%), lightheadedness (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (8%), abnormal ECG (7%), hypotension (6%), proarrhythmia (5%), syncope (5%), CHF (5%), torsade de pointes (dose related; 1% to 4%), peripheral vascular disorders (3%), ventricular tachycardia worsened (1%), QT",
"     <sub>",
"      c",
"     </sub>",
"     interval prolongation (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (8%), sleep problems (8%), mental confusion (6%), anxiety (4%), depression (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Itching/rash (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Sexual ability decreased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (10%), diarrhea (7%), stomach discomfort (3% to 6%), flatulence (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Extremity pain (7%), paresthesia (4%), back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual problems (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory problems (5% to 8%), asthma (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, bronchiolitis obliterans with organized pneumonia (BOOP), cold extremities, diaphoresis, eosinophilia, leukocytoclastic vasculitis, leukopenia, paralysis, phlebitis, photosensitivity reaction, pruritus, pulmonary edema, Raynaud's phenomenon, red crusted skin, retroperitoneal fibrosis, serum transaminases increased, skin necrosis after extravasation, thrombocytopenia, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F222476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sotalol or any component of the formulation; bronchial asthma; sinus bradycardia; second- or  third-degree AV block (unless a functioning pacemaker is present); congenital or acquired long QT syndromes; cardiogenic shock; uncontrolled heart failure",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional contraindications: Betapace AF&reg; and the injectable formulation: Baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval &gt;450 msec; bronchospastic conditions; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute; serum potassium &lt;4 mEq/L; sick sinus syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F222457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia/hypotension: May cause bradycardia and hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects:",
"     <b>",
"      [U.S. Boxed Warning]: Sotalol injection: Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation (ie, torsade de pointes).  Do not initiate if baseline QT",
"      <sub>",
"       c",
"      </sub>",
"      interval is &gt;450 msec. If QT",
"      <sub>",
"       c",
"      </sub>",
"      exceeds 500 msec during therapy, reduce the dose, prolong the infusion duration, or discontinue use.",
"     </b>",
"     If while on oral sotalol therapy baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval is &gt;500 msec, use I.V. sotalol with particular caution; serious consideration should be given to reducing the dose or discontinuing I.V. sotalol when QT",
"     <sub>",
"      c",
"     </sub>",
"     exceeds 520 msec. QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation is directly related to the concentration of sotalol; reduced creatinine clearance, female gender, and large doses increase the risk of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and subsequent torsade de pointes. Monitor and adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalances: Correct electrolyte imbalances before initiating (especially hypokalemia and hypomagnesemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction: Use with caution within the first 2 weeks post-MI especially in patients with markedly impaired ventricular function (experience limited).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Adjust dosing interval based on creatinine clearance to decrease risk of proarrhythmia; QT interval prolongation is directly related to sotalol concentration.",
"     </b>",
"     Creatinine clearance must be calculated with dose initiation and dose increases. Betapace AF&reg; and the injectable formulation are contraindicated in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs: Concurrent use with other QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs (including Class I and Class III antiarrhythmics) and use within 3 months of discontinuing amiodarone is generally not recommended. To reduce the chance of excessive QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolongation, withhold QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs for at least 3 half-lives (or 3 months for amiodarone) before initiating sotalol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary. In the treatment of atrial fibrillation, avoid antiarrhythmics as first-line treatment. In older adults, data suggests rate control may provide more benefits than risks compared to rhythm control for most patients (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchange:",
"     <b>",
"      [U.S. Boxed Warning]: Betapace&reg; should not be substituted for Betapace&reg; AF; Betapace&reg; AF is distributed with an educational insert specifically for patients with atrial fibrillation/flutter.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dose initiation/increases:",
"     <b>",
"      [U.S. Boxed Warning]: Manufacturer recommends initiation (or reinitiation) and dose increases be done in a hospital setting with continuous monitoring and staff familiar with the recognition and treatment of life-threatening arrhythmias.",
"     </b>",
"     Some experts will initiate therapy on an outpatient basis in a patient without heart disease or bradycardia, who has a baseline uncorrected QT interval &lt;450 msec, and normal serum potassium and magnesium levels; close ECG monitoring during this time is necessary. ACC/AHA guidelines for management of atrial fibrillation also recommend that for outpatient initiation the patient not have risk factors predisposing to drug-induced ventricular proarrhythmia (Fuster, 2006). Dosage should be adjusted gradually with 3 days between dosing increments to achieve steady-state concentrations, and to allow time to monitor QT intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F222462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F222494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Sotalol peak serum concentrations may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid ephedra (may worsen arrhythmia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F222480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies sotalol as pregnancy category B. Sotalol crosses the placenta and is found in amniotic fluid. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother; however, sotalol is currently not recommended for the initial treatment of hypertension in pregnancy. Because sotalol crosses the placenta in concentrations similar to the maternal serum, it has been used for the treatment of fetal atrial flutter or fetal supraventricular tachycardia without hydrops. The clearance of sotalol is increased during the third trimester of pregnancy, but other pharmacokinetic parameters do not significantly differ from nonpregnant values.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F222507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/consider risk:benefit (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F222481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sotalol is excreted into breast milk in concentrations higher than those found in the maternal serum. Although adverse events in nursing infants have not been observed in case reports, close monitoring for bradycardia, hypotension, respiratory distress, and hypoglycemia is advised. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F222482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F222479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sotalol HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/10 mL (10 mL): $78.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Betapace AF Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (60): $259.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (60): $346.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (60): $433.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Betapace Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $473.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $631.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (100): $789.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sorine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (1): $2.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (1): $3.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (1): $4.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (1): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sotalol HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $241.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $341.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (100): $427.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $555.59",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F222466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum creatinine, magnesium, potassium; heart rate, blood pressure; ECG (eg, QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, PR interval). If baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;450 msec (or JT interval &gt;330 msec if QRS over 100 msec), sotalol is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For oral use (Betapace AF&reg;) during initiation period, monitor QT",
"     <sub>",
"      c",
"     </sub>",
"     interval 2-4 hours after each dose. If QT",
"     <sub>",
"      c",
"     </sub>",
"     interval &ge;500 msec, discontinue use; if QT",
"     <sub>",
"      c",
"     </sub>",
"     interval &lt;500 msec after 3 days (after fifth or sixth dose if patient receiving once-daily dosing), patient may be discharged on current regimen. Monitor QT",
"     <sub>",
"      c",
"     </sub>",
"     interval periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For I.V. use, measure QT",
"     <sub>",
"      c",
"     </sub>",
"     interval after completion of each infusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alosot (UY);",
"     </li>",
"     <li>",
"      Beta-Cardone (GB, IE);",
"     </li>",
"     <li>",
"      Betacor (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Betades (IT);",
"     </li>",
"     <li>",
"      Cardol (AU, TW);",
"     </li>",
"     <li>",
"      Darob (AT, BG, HR);",
"     </li>",
"     <li>",
"      Gilucor (HR, HU);",
"     </li>",
"     <li>",
"      Hipecor (CN);",
"     </li>",
"     <li>",
"      Jutalex (DE);",
"     </li>",
"     <li>",
"      Rentibloc (KP);",
"     </li>",
"     <li>",
"      Solavert (AU);",
"     </li>",
"     <li>",
"      Sotacor (AR, AT, AU, BF, BJ, BR, CI, CL, CO, DK, ET, FI, GB, GH, GM, GN, HK, ID, IE, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, SC, SD, SE, SL, SN, TH, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Sotagard (IN);",
"     </li>",
"     <li>",
"      Sotahexal (DE, HU, SG, ZA);",
"     </li>",
"     <li>",
"      Sotalex (BE, CH, CZ, DE, FR, GR, HN, HU, IT, LU, PH, PL, PT, RU);",
"     </li>",
"     <li>",
"      Sotalex Mite (EE);",
"     </li>",
"     <li>",
"      Sotalol Knoll (HU);",
"     </li>",
"     <li>",
"      Sotapor (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F222456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Beta-blocker which contains both beta-adrenoreceptor-blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) properties",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Class II effects: Increased sinus cycle length, slowed heart rate, decreased AV nodal conduction, and increased AV nodal refractoriness Sotalol has both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptor blocking activity. The beta-blocking effect of sotalol is a noncardioselective (half maximal at about 80 mg/day and maximal at doses of 320-640 mg/day). Significant beta-blockade occurs at oral doses as low as 25 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Class III effects: Prolongation of the atrial and ventricular monophasic action potentials, and effective refractory prolongation of atrial muscle, ventricular muscle, and atrioventricular accessory pathways in both the antegrade and retrograde directions. Sotalol is a racemic mixture of",
"     <i>",
"      d-",
"     </i>",
"     and",
"     <i>",
"      l-",
"     </i>",
"     sotalol; both isomers have similar Class III antiarrhythmic effects while the",
"     <i>",
"      l-",
"     </i>",
"     isomer is responsible for virtually all of the beta-blocking activity. The Class III effects are seen only at oral doses &ge;160 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F222475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Rapid, 1-2 hours; when administered I.V. for ongoing VT over 5 minutes, onset of action is ~5-10 minutes (Ho, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 8-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Decreased 20% to 30% by meals compared to fasting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.2-2.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 90% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 12 hours; Children: 9.5 hours; terminal half-life decreases with age &lt;2 years (time to steady state may be &ge;1 week in neonates); increases with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 2.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Comparison of Antiarrhythmic-Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Near-Fatal Ventricular Arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(22):1576-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/9411221/pubmed\" id=\"9411221\" target=\"_blank\">",
"        9411221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ho DS, Zecchin RP, Cooper MJ, et al, &ldquo;Rapid Intravenous Infusion of d-l Sotalol: Time to Onset of Effects on Ventricular Refractoriness, and Safety,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1995, 16(1):81-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/7737227/pubmed\" id=\"7737227\" target=\"_blank\">",
"        7737227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ho DS, Zecchin RP, Richards DA, et al, &ldquo;Double-Blind Trial of Lignocaine versus Sotalol for Acute Termination of Spontaneous Sustained Ventricular Tachycardia,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 344(8914):18-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/7912296/pubmed\" id=\"7912296\" target=\"_blank\">",
"        7912296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, \"Effect of Perioperative Beta-Blockade in Patients With Diabetes Undergoing Major Noncardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006,  332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuhlkamp V, Mewis C, Mermi J, et al, &ldquo;Suppression of Sustained Ventricular Tachyarrhythmias: A Comparison of d,1-Sotalol With No Antiarrhythmic Drug Treatment,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/9935007/pubmed\" id=\"9935007\" target=\"_blank\">",
"        9935007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mason JW, &ldquo;A Comparison of Seven Antiarrhythmic Drugs in Patients With Ventricular Tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(7):452-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/8332150/pubmed\" id=\"8332150\" target=\"_blank\">",
"        8332150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pacifico A, Hohnloser SH, Williams JH, et al, &ldquo;Prevention of Implantable-Defibrillator Shocks by Treatment With Sotalol. d,1-Sotalol Implantable Cardioverter-Defibrillator Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(24):1855-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/10369848/pubmed\" id=\"10369848\" target=\"_blank\">",
"        10369848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waldo AL, Camm AJ, deRuyter H, et al, &ldquo;Effect of d-sotalol on Mortality in Patients With Left Ventricular Dysfunction After Recent and Remote Myocardial Infarction. The SWORD Investigators. Survival With Oral d-Sotalol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1996, 348(9019):7-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/8691967/pubmed\" id=\"8691967\" target=\"_blank\">",
"        8691967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, \"The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, A Randomized Controlled Trial,\"",
"      <i>",
"       Am Heart J",
"      </i>",
"      2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/17070177 /pubmed\" id=\"17070177 \" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(5):247-346.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/13/21721/abstract-text/16949478 /pubmed\" id=\"16949478 \" target=\"_blank\">",
"        16949478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9941 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21721=[""].join("\n");
var outline_f21_13_21721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709415\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222498\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222538\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222502\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222521\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222503\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222504\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9830566\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222468\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222453\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222472\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9830565\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222471\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9830364\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222546\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222536\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222476\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222457\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300075\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222462\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222494\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222464\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222480\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222507\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222481\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222482\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222479\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222466\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038831\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222456\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222475\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9941|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/57/41880\" title=\"Age nomogram\">",
"      Age nomogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/22/33125?source=related_link\">",
"      Sotalol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=related_link\">",
"      Sotalol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_13_21722="Distal radius fractures in adults";
var content_f21_13_21722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Distal radius fractures in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21722/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21722/contributors\">",
"     David J Petron, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21722/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21722/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/13/21722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/13/21722/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/13/21722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distal radius is the most common fracture site in the upper extremity. Such injuries account for approximately one-sixth of fractures treated in US emergency departments [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/1\">",
"     1",
"    </a>",
"    ]. The Colles fracture is the most common. Familiarity with wrist anatomy and the natural history of major fracture types is essential for appropriate management of distal radius fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/2\">",
"     2",
"    </a>",
"    ]. This topic review will discuss the evaluation and management of distal radius fractures in adults. Other wrist injuries are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=see_link\">",
"     \"Evaluation of the adult with acute wrist pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of over 1.4 million US emergency department (ED) visits found that hand and forearm fractures account for 1.5 percent of all visits [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/1\">",
"     1",
"    </a>",
"    ]. Of these, fractures of the radius",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulna comprise the largest portion (44 percent).",
"   </p>",
"   <p>",
"    The majority of distal radius fractures occur as isolated injuries in two distinct populations: youth involved in sport who sustain a relatively high-energy fall, and seniors with osteoporotic bone who sustain a low-energy fall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Athletics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of wrist fractures among young people varies according to the local popularity of different physical activities. A Scottish study of distal radius fractures related to sport found that football (ie, soccer) produced 50 percent of fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/3\">",
"     3",
"    </a>",
"    ]. Play on artificial turf increased the likelihood of fracture by a factor of five. Skiing, dancing, and rugby caused 12, 9, and 7 percent of wrist fractures, respectively. More severe injuries occurred as a result of skiing, horseback riding, and dancing.",
"   </p>",
"   <p>",
"    The increasingly popular sport of snowboarding has a high rate of associated extremity fractures, including those of the distal radius. Physicians at a Japanese hospital caring for more than 10 ski areas evaluated over 5000 snowboarders for injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/4\">",
"     4",
"    </a>",
"    ]. They found most distal radius fractures occurred in patients in their twenties (82.3 percent) without extensive snowboarding experience (42 percent novices; 48 percent intermediates). Ninety-four percent of patients had not received professional instruction, and 87 percent were not wearing protective equipment. Although less likely to be injured, more experienced snowboarders were more likely to sustain a complex intraarticular fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Geriatric population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both age and gender play a role in the risk of distal radius fracture. At 50 years of age, a white woman living in the United States or Northern Europe has approximately a 15 percent lifetime risk of a distal radius fracture; a man in the same regions has a lifetime risk of just over 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One large, prospective study of distal radius fractures among Caucasian women with osteoporosis, over the age of 65, involved in low-energy falls, found three statistically significant, independent risk factors: decreased bone density at the distal radius (RR = 1.8), a history of recurrent falls (RR = 1.6), and previous fracture after age 50 (RR = 1.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/6\">",
"     6",
"    </a>",
"    ]. For women over 75 years of age, dementia was an additional risk factor. Use of oral estrogen was found to be protective, and intraarticular fractures were more than twice as frequent in women with diabetes.",
"   </p>",
"   <p>",
"    Among elderly men, distal radius fracture appears to be an early and sensitive marker of skeletal fragility [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/7\">",
"     7",
"    </a>",
"    ]. More than any other fracture type, distal radius fractures correlate with a higher absolute risk for hip fracture in men (among women spinal compression fracture correlates more closely). A smaller study found shorter-than-expected life expectancy among patients with distal radius fractures when compared with peers of comparable age, gender, and comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/8\">",
"     8",
"    </a>",
"    ]. After sustaining this fracture, men were twice as likely to die as women with the same injury and did so almost twice as quickly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32473?source=see_link\">",
"     \"Epidemiology and etiology of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although older patients sustaining low-energy distal radius fractures represent an important population for osteoporosis screening and treatment, the opportunity is often squandered. One Canadian study evaluated osteoporosis follow-up and treatment in a group of 156 patients who sustained a low-energy distal radius fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/9\">",
"     9",
"    </a>",
"    ]. They found that 32 percent of patients were receiving osteoporosis treatment before their injury, but after fracturing their radius only 21 percent more received osteoporosis screening, and only a few more began receiving a bisphosphonate or hormone replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H395494646\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy of the wrist is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14039?source=see_link\">",
"     \"Anatomy and basic biomechanics of the wrist\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanism of distal radius fractures is Falling On an Out-Stretched Hand (sometimes abbreviated as FOOSH), with the wrist in extension. Minimal force is needed to produce a distal radius fracture in osteoporotic bone, and injury can occur after a fall from standing height or lower.",
"   </p>",
"   <p>",
"    In healthy young patients, distal radius fractures often occur after violent injuries directly to the bone or by a compression load driving the scaphoid or lunate into the distal radius, producing a \"die-punch\" fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/2\">",
"     2",
"    </a>",
"    ]. Such high-energy fractures are more likely to be comminuted and intraarticular, and to occur in association with other significant injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with a distal radius fracture usually describes falling onto their outstretched hand or sustaining a blow to the wrist and complains of wrist pain, and possibly deformity. In addition to standard inquiries about the mechanism of injury, the clinician should ask about any previous wrist injuries or surgery, and any resultant abnormal anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/10\">",
"     10",
"    </a>",
"    ]. Also important are medical conditions affecting the injured extremity, such as carpal tunnel syndrome or peripheral vascular disease.",
"   </p>",
"   <p>",
"    The clinician should inspect the injured extremity for swelling, deformity, and evidence of a possible open fracture. Swelling may or may not have developed by the time of presentation. Obvious deformities, such as the classic \"dinner-fork\" deformity (",
"    <a class=\"graphic graphic_figure graphicRef78559 \" href=\"UTD.htm?27/24/28047\">",
"     figure 1",
"    </a>",
"    ) associated with Colles' fractures, can occur, but the extremity may appear normal.",
"   </p>",
"   <p>",
"    Examination includes an assessment of neurovascular status, including motor and sensory function of the median, radial, and ulnar nerves. Particular attention should be paid to sensation in the thumb and index fingers because acute median nerve compression is common, especially with severely displaced fractures. The clinician should assess circulation by palpating the radial pulse and testing capillary refill of the nail beds and fingertips. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Range of motion of the wrist, including supination, pronation, flexion, and extension should be evaluated if possible. Ulnar deviation with palpation of the anatomic snuffbox is important to ascertain the presence of a scaphoid fracture. Clinical evaluation of a distal radioulnar joint (DRUJ) injury associated with a distal radius fracture is difficult. Ulnar-sided wrist pain and tenderness may be present due to a DRUJ or ulnar styloid injury.",
"   </p>",
"   <p>",
"    In order not to miss associated injuries, the clinician should examine the involved extremity in its entirety, particularly the elbow and shoulder joints. A detailed description of the examination of the wrist and other joints is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=see_link\">",
"     \"Evaluation of the adult with acute wrist pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14983?source=see_link\">",
"     \"Evaluation of elbow pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When reading radiographs of distal radius fractures, clinicians should seek to answer four important questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is there loss of normal anatomy (eg, fracture displacement or angulation, loss of radial height)? (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Anatomic landmarks and measurements'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Is there involvement of the radiocarpal or distal radioulnar joint?",
"     </li>",
"     <li>",
"      If joints are involved, is there discontinuity of the articular surface (ie, articular step-off) or diastasis (ie, separation) of the articular fragments?",
"     </li>",
"     <li>",
"      Are high-risk features present (eg, severe comminution, articular step-off &gt;2 mm, fracture-dislocation)? (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anatomic landmarks and measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate assessment of standard radiographs is essential for appropriate management [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Radiographic evaluation of the distal radius includes true posterior-anterior (PA) and true lateral projections. Oblique radiographs often are included as a supplemental view [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"     13",
"    </a>",
"    ]. Each view contains a small number of important landmarks and measurements for proper interpretation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Posterior-anterior (PA) x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;Landmarks on the PA projection include the radial and ulnar styloids, the distal radioulnar joint (DRUJ), and the radiocarpal joint, including the proximal carpal bones. Important radiographic measurements include radial inclination, radial height, and ulnar variance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radial inclination (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73876 \" href=\"UTD.htm?20/21/20817\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef82065 \" href=\"UTD.htm?8/13/8407\">",
"       figure 2",
"      </a>",
"      ) is the angle between one line drawn perpendicular to the long axis of the radius and a second line drawn between the distal tip of the radial styloid and the central reference point (CRP). The CRP lies midway between the palmar ulnar corner and the dorsal ulnar corner of the distal radius (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62135 \" href=\"UTD.htm?6/1/6161\">",
"       image 2",
"      </a>",
"      ). The average angle is approximately 20 to 25 degrees, although there are slight gender differences (24.7 &plusmn; 2.5 for women; 22.5 &plusmn; 2.1 for men) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"       13",
"      </a>",
"      ]. The angle is often smaller with distal radius fractures.",
"     </li>",
"     <li>",
"      Radial height (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73876 \" href=\"UTD.htm?20/21/20817\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef82065 \" href=\"UTD.htm?8/13/8407\">",
"       figure 2",
"      </a>",
"      ) is the distance between two lines drawn perpendicular to the longitudinal axis of the radial shaft: one through the distal tip of the radial styloid and the second through the CRP. Normal height averages 11.6 &plusmn; 1.6 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"       13",
"      </a>",
"      ]. The measured height is often smaller with distal radius fractures.",
"     </li>",
"     <li>",
"      Ulnar variance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73876 \" href=\"UTD.htm?20/21/20817\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef82065 \" href=\"UTD.htm?8/13/8407\">",
"       figure 2",
"      </a>",
"      ) is the distance between two lines drawn perpendicular to the longitudinal axis of the radial shaft: one through the distal articular surface of the ulnar head and the second through the CRP. Normally, the radial surface is distal to the ulnar surface by 1 to 2 mm (negative ulnar variance) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"       13",
"      </a>",
"      ]. When the ulnar surface is distal to the radial surface (positive ulnar variance), the biomechanics of the wrist can be impaired, especially if the distance is 5 mm greater than the contralateral wrist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lateral x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a true lateral projection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52912 \" href=\"UTD.htm?8/34/8736\">",
"     image 3",
"    </a>",
"    ), the radius and ulna should be superimposed, and the pisiform projected over the distal pole of the scaphoid. If the pisiform is found dorsal to the scaphoid, the patient is in relative pronation; if found palmar, the patient is in relative supination. Normally, the lunate is seated within the fossa of the distal radius, and the curvature of their articular surfaces should correspond. The central axis of the lunate should be collinear with the central axis of the radius. Palmar migration is a sign of radiocarpal instability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important measurement on a lateral projection is palmar tilt (ie, volar tilt). AP distance may also be helpful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palmar tilt (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52912 \" href=\"UTD.htm?8/34/8736\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62727 \" href=\"UTD.htm?35/3/35890\">",
"       figure 3",
"      </a>",
"      ) is the angle formed by the intersection of one line perpendicular to the longitudinal axis of the radial shaft and a second line drawn through the apices of the palmar and the dorsal rims of the radius. The normal palmar tilt on a standard lateral projection averages 11.2 &plusmn; 4.6 degrees and does not differ between genders [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"       13",
"      </a>",
"      ]. A smaller palmar tilt as a result of fracture is a risk factor for subsequent pain and disability.",
"     </li>",
"     <li>",
"      AP distance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52912 \" href=\"UTD.htm?8/34/8736\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62727 \" href=\"UTD.htm?35/3/35890\">",
"       figure 3",
"      </a>",
"      ) lies between the apices of the dorsal and palmar rims of the radius. Normally, AP distance should be slightly larger than the width of the lunate, and it averages 19.1 &plusmn; 1.7 mm. It is significantly larger in males (20.4 &plusmn; 1.1) versus females (17.8 &plusmn; 1.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"       13",
"      </a>",
"      ]. It can increase as a result of axial impaction injuries and suggests articular step-off.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal radius fractures can be described using either a fragment-specific classification [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"     13",
"    </a>",
"    ] or the standard Frykman classification. The Frykman classification system divides the fractures among four main groups based upon joint involvement. Within each major grouping, fractures with even numbers involve a concomitant ulnar styloid fracture. Frykman categories are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Types",
"      <span class=\"nowrap\">",
"       I/II:",
"      </span>",
"      Completely extraarticular; complications are uncommon once anatomic alignment has been achieved (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61535 graphicRef74330 graphicRef78794 \" href=\"UTD.htm?8/58/9125\">",
"       image 4A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Types",
"      <span class=\"nowrap\">",
"       III/IV:",
"      </span>",
"      Extend into the radiocarpal joint (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66573 graphicRef79669 \" href=\"UTD.htm?34/19/35122\">",
"       image 5A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Types",
"      <span class=\"nowrap\">",
"       V/VI:",
"      </span>",
"      Extend into the distal radioulnar joint (DRUJ)",
"     </li>",
"     <li>",
"      Types",
"      <span class=\"nowrap\">",
"       VII/VIII:",
"      </span>",
"      Involve both radiocarpal and DRUJ articular surfaces and are highly unstable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two common eponyms associated with distal radius fractures are Colles and Smith. Colles' fractures involve dorsal displacement of the distal radius fragment (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61535 graphicRef74330 graphicRef78794 \" href=\"UTD.htm?8/58/9125\">",
"     image 4A-C",
"    </a>",
"    ); Smith's fractures involve palmar displacement of the distal radius fragment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fracture dislocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major types of radiocarpal fracture dislocations exist: Barton's and Hutchinson's.",
"   </p>",
"   <p>",
"    Barton's fractures are separated into palmar and dorsal. They are best seen on lateral radiographs. Palmar Barton's fractures occur when the palmar radiocarpal ligaments avulse a radial fragment and displace the radiocarpal unit volarly. In a dorsal Barton's fracture, the dorsal radiocarpal ligaments avulse a radial fragment and displace the radiocarpal unit dorsally. In both types, the distal radius fragment maintains articulation with the carpus, accounting for the dislocation and instability. Closed reduction can be attempted, but these fractures are very unstable and reduction is usually lost. Barton's fractures generally require operative fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second type of fracture dislocation carries the eponym of Hutchinson's fracture, and it is also called the chauffeur's fracture. The typical mechanism is a direct blow to the radial styloid (such as might have occurred when the starting crank of an early automobile suddenly reversed with a backfire striking the chauffeur's wrist), or a fall back onto an outstretched hand held in ulnar deviation and supination. Such mechanisms cause the radioscaphocapitate ligament to avulse a large fragment of the radial styloid. This injury frequently results in concomitant lunate dislocation or scapholunate dissociation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H395494673\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of a distal radius fracture is made on the basis of diagnostic imaging studies, typically plain radiographs of the wrist. Radiographs are obtained when the diagnosis is suspected on the basis of a suggestive history, often involving a fall onto an outstretched hand, and examination findings, including pain, tenderness, and possibly deformity at the wrist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H395494681\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism most often responsible for distal radius fractures, fall onto an outstretched hand, is associated with a number of other injuries that should be considered when evaluating patients with acute wrist pain from direct trauma. These injuries include fractures of the scaphoid and other carpal bones, injury to the distal radioulnar joint (DRUJ) or triangular fibrocartilage complex, and ligamentous injuries, which manifest differently depending upon the involved ligaments (eg, lunate or perilunate dislocation, scapholunate dissociation). Scaphoid injuries are common and often associated with tenderness in the anatomic snuffbox (",
"    <a class=\"graphic graphic_picture graphicRef82859 \" href=\"UTD.htm?35/44/36547\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although clinical findings may vary somewhat depending upon the injury, there is substantial overlap in the presentations of many of the injuries listed here. Furthermore, two or more injuries may occur simultaneously as a result of the same trauma. Therefore, the only reliable method for distinguishing among injuries is diagnostic imaging, typically starting with plain radiographs of the wrist. The diagnostic approach to patients with acute wrist pain and the diagnosis and management of other major injuries that may be sustained by falling onto an outstretched wrist are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of the adult with acute wrist pain\", section on 'Wrist trauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many distal radius fractures can be managed by knowledgeable primary care clinicians. Conditions requiring emergent referral to an orthopedic surgeon include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open fractures",
"     </li>",
"     <li>",
"      Fractures associated with an acute neuropathy or compartment syndrome",
"     </li>",
"     <li>",
"      Fractures associated with circulatory compromise in the hand (vascular surgical consultation may also be required in this circumstance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases of neurologic or vascular compromise, immediate closed reduction of any displaced fracture should be performed, after providing analgesia, to attempt to alleviate symptoms. Persistent deficits despite reduction mandate emergent referral to an appropriate surgeon, or transfer if such care is unavailable.",
"   </p>",
"   <p>",
"    Unstable fractures and those at high risk for complications should also be referred to an orthopedic surgeon. The following conditions warrant orthopedic referral:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palmarly displaced (eg, Smith's) fractures (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Classification'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Articular step-off greater than 2 mm",
"     </li>",
"     <li>",
"      Large ulnar styloid fractures (ie, most or all of the styloid) with displaced fragments at the styloid base; these have an increased risk of distal radioulnar joint (DRUJ) instability [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fracture dislocations (ie, Barton's or Hutchinson's) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Fracture dislocations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Distal radius fractures associated with scaphoid fractures or scapholunate ligament injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/18,19\">",
"       18,19",
"      </a>",
"      ] (Radial styloid fractures are often associated with scapholunate injuries and such fractures are generally referred to an orthopedic surgeon)",
"     </li>",
"     <li>",
"      Fractures with significant displacement or comminution; these are unstable and likely to lose position even if initial reduction is near-anatomic",
"     </li>",
"     <li>",
"      Fractures likely to be unstable and unamenable to conservative treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The parameters for instability are poorly defined in the literature and vary with patient age and functional demands. Clinicians should be particularly concerned about patients who are physiologically young and have sustained high-energy, comminuted injuries. The presence of the following conditions on initial radiographs suggests fracture instability and the need for referral [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater than 20 degrees of dorsal angulation",
"     </li>",
"     <li>",
"      Fracture displacement in any direction greater than two-thirds the width of the radial shaft",
"     </li>",
"     <li>",
"      Metaphyseal comminution with more than 5 mm of radial shortening (normal height = 10 to 13 mm)",
"     </li>",
"     <li>",
"      Ulnar variance greater than 5 mm compared with the contralateral wrist (normal variance is 0 to -2 mm)",
"     </li>",
"     <li>",
"      Intraarticular component (especially involving the DRUJ)",
"     </li>",
"     <li>",
"      Advanced osteoporosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple scoring systems have been developed to predict instability in fractures of the distal radius [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. However, these formulas have tended to underestimate fracture instability, and their use is not recommended. Instead, we suggest referral for any of the factors listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of emergent conditions and the decision of whether to perform a fracture reduction comprise the most important steps in the acute management of distal radius fractures. If significant nerve injury (eg, paralysis, severe weakness) or vascular compromise is present, immediate reduction of the displaced fracture, with analgesia, is necessary to attempt to alleviate these symptoms. Persistent symptoms despite reduction mandate emergent consultation with the appropriate surgical specialist. Compartment syndrome is an emergency requiring immediate surgical release. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Early complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Should no emergent conditions exist, immediate reduction is not required, and appropriate treatment depends upon the type of fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nondisplaced extra-articular fractures (Frykman types I/II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;These fractures are relatively stable and can be treated with a well-molded sugar tong, reverse sugar tong, or double sugar tong splint. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H12#H12\">",
"     \"Splinting of musculoskeletal injuries\", section on 'Sugar tong splints'",
"    </a>",
"    .) The application of a circumferential cast in the acute setting increases the risk of distal ischemia and carpal tunnel syndrome, and it should not be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proper positioning within the splint has the elbow flexed to 90 degrees and the arm in neutral position (ie, without forearm supination or pronation, and without wrist flexion or extension). During the first several days following injury, the patient should elevate the arm, apply ice to the fracture frequently (while keeping the splint dry), begin active range of motion of the shoulder and fingers, and use analgesics as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/3\">",
"     3",
"    </a>",
"    ]. Opioids may be necessary; a short course of nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Displaced fractures (Frykman types I-VIII)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Displaced fractures with neurovascular compromise warrant an immediate attempt at closed reduction. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Early complications'",
"    </a>",
"    below.) Immediate closed reduction by an experienced clinician is appropriate, but not required, for displaced fractures without neurovascular compromise or radiographic evidence of instability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Radiographic findings'",
"    </a>",
"    above.) If a clinician capable of performing a reduction is unavailable, the provider may immobilize the fracture, provide appropriate analgesia, and discharge the patient, provided follow-up the next day for reduction by an orthopedist has been arranged.",
"   </p>",
"   <p>",
"    Criteria for adequate reduction in a patient with high functional demands include (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Classification'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No dorsal tilt of the distal radial articular surface",
"     </li>",
"     <li>",
"      Less than 5 mm of radial shortening",
"     </li>",
"     <li>",
"      Less than 2 mm of displacement of fracture fragments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Substantial soft tissue swelling often accompanies displaced fractures, so splinting is recommended for postreduction immobilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H12#H12\">",
"     \"Splinting of musculoskeletal injuries\", section on 'Sugar tong splints'",
"    </a>",
"    .) The application of a circumferential cast in the acute setting increases the risk of distal ischemia and carpal tunnel syndrome, and it should not be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the first several days following injury, the patient should elevate the arm, apply ice to the fracture frequently (while keeping the splint dry), begin active range of motion of the shoulder and fingers, and use analgesics as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/3\">",
"     3",
"    </a>",
"    ]. Opioids may be necessary; a short course of nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FRACTURE REDUCTION BASICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of neurologic or vascular compromise, immediate closed reduction of any displaced fracture should be performed. Persistent deficits despite reduction mandate emergent referral to an appropriate surgeon, or transfer if such care is unavailable. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    above.) Should no emergent conditions exist, immediate reduction is not required. Adequate anesthesia must be obtained prior to reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hematoma block",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hematoma block, with or without systemic opioids, provides adequate analgesia for reduction of most displaced distal radius fractures. Hematoma blocks are safe and easy to perform.",
"   </p>",
"   <p>",
"    First, the skin over and around the fracture site is prepared with an antiseptic solution (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ). Sterile technique should be maintained throughout the procedure. Next, a 10 mL syringe is filled with 5 to 8 mL of one percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    without epinephrine. A 22-gauge needle is attached to this syringe. The clinician then gently palpates the dorsum of the wrist to locate the fracture step-off with one hand, and inserts the needle, also on the dorsal aspect of the wrist, with the other. The needle is advanced directly into the fracture site. The clinician draws back continuously on the syringe while advancing the needle. Aspiration is maintained until a flashback of blood confirms placement of the needle tip in the fracture hematoma. The mixture of blood and lidocaine is then injected directly into the fracture site. Some clinicians perform repeated aspirations and reinjections to disperse the anesthetic more completely before removing the",
"    <span class=\"nowrap\">",
"     needle.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Reduction techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traction/counter-traction",
"    is critical to reduction. This can be achieved with or without finger traps (",
"    <a class=\"graphic graphic_figure graphicRef78570 \" href=\"UTD.htm?3/33/3615\">",
"     figure 4",
"    </a>",
"    ). The two approaches do not differ in the ultimate alignment attained or in the rate of failure to maintain reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the method used to reduce the fracture, finger traps are a useful adjunct before the procedure is attempted. Traction is applied by attaching the finger traps to the thumb, index, and middle fingers, while keeping the elbow flexed at 90 degrees and the forearm in neutral rotation. Five to 10 pounds (two to five kilograms) of downward traction is placed on the distal humerus for at least five minutes before any reduction is attempted. This enables muscular relaxation and helps distract the fracture fragments, bringing the radius closer to normal length.",
"   </p>",
"   <p>",
"    Active reduction can be performed with the patient still in the finger traps. For Colles' type fractures, the examiner's thumbs are placed on the dorsal aspect of the distal fracture fragment, while the fingers are placed on the palmar forearm just proximal to the fracture line. While applying downward axial traction to the proximal fragment, the distal fragment is pushed distally, palmarly, and ulnarly to eliminate the dorsal displacement and radial shortening.",
"   </p>",
"   <p>",
"    A sugar tong, reverse-sugar tong, or double sugar tong splint is then applied and molded with the patient still in the finger traps [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H12#H12\">",
"     \"Splinting of musculoskeletal injuries\", section on 'Sugar tong splints'",
"    </a>",
"    .) A three-point contact molding technique is used to help hold the reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/27\">",
"     27",
"    </a>",
"    ]. For Colles' type fractures, ideal immobilization for the first two weeks consists of 15 degrees of palmar flexion, 10 to 15 degrees of ulnar deviation, and slight pronation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manual reduction can also be performed without finger traps, with the help of an assistant. The assistant provides counter-traction by holding the elbow. The clinician then supinates the patient's forearm with one hand while applying longitudinal traction to the distal fragment with the other hand and thumb. Next, the fracture is disimpacted by applying dorsal angulation (ie, accentuating the fracture pattern). Finally, the reduction is completed by pronating the forearm and wrist, followed by the application of some ulnar deviation, to correct the radial and dorsal angulation. The fracture is held in this position while a splint is applied and molded in the fashion described immediately above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of distal radius fractures varies according to the patient's health, functional needs, and the injury sustained. Active patients with high functional needs require anatomic reductions, and they often need surgical fixation.",
"   </p>",
"   <p>",
"    The most fundamental decision is whether to treat conservatively or surgically. Clinicians should consider such medical factors as bone quality, comorbidities, and functional demand. Fracture characteristics, associated injuries, risk of complications, and clinician experience with fracture management are also relevant. As an example, a 16-year-old skateboarder with a comminuted, displaced, intraarticular fracture requires surgical repair to achieve anatomic alignment; a sedentary 80-year-old with an identical injury needs immobilization and occupational rehabilitation. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Geriatric management'",
"    </a>",
"    below.) Finally, clinicians should inquire about patient preferences and social circumstances.",
"   </p>",
"   <p>",
"    Conservative management with closed reduction and immobilization is appropriate for fractures that are reducible by closed manipulation and will remain stable thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/28\">",
"     28",
"    </a>",
"    ]. A systematic review found insufficient evidence to determine which conservative treatments are most appropriate for common adult distal radius fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/29\">",
"     29",
"    </a>",
"    ]. Our recommendations below are based upon the limited literature assessing treatment of these fractures and our clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nondisplaced extra-articular (Frykman types I/II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are seen three to five days following injury to allow swelling to subside. The clinician should remove the splint, assess neurovascular status, and obtain radiographs of the arm out of the splint to confirm there is no loss of position.",
"   </p>",
"   <p>",
"    If the fracture remains nondisplaced or minimally displaced, the clinician applies a short arm cast. The cast should extend from the distal palmar crease to within 5 cm of the antecubital fossa, with the wrist in neutral position. Patients should be seen in follow-up every two to three weeks thereafter until healing is complete. Radiographs are taken at the initial postcasting visit, at two weeks, and then sometime between four and six weeks after injury to confirm proper alignment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient's wrist and forearm should remain immobilized until there is evidence of radiographic healing or the fracture site is nontender, generally four to six weeks postinjury. At this point, the patient can use a wrist brace in lieu of a cast. Complete healing usually requires six to eight weeks.",
"   </p>",
"   <p>",
"    For patients over 60 years of age, the period of immobilization should be kept to a minimum to avoid post-immobilization stiffness. Early transition to a wrist splint may be helpful depending on fracture stability. In one randomized trial, patients treated with a wrist splint were more satisfied and regained function sooner than patients immobilized in a cast [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence guiding the appropriate period of fracture immobilization in the geriatric population is lacking. Nevertheless, we think that older patients who meet the following criteria can be removed from their cast and placed in a wrist splint as early as two to three weeks following injury:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extraarticular fracture of the distal radius",
"     </li>",
"     <li>",
"      Minimal comminution present",
"     </li>",
"     <li>",
"      Reduction was NOT necessary",
"     </li>",
"     <li>",
"      Functional demands are few",
"     </li>",
"     <li>",
"      Risk of fall or reinjury is low",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Displaced (Frykman types I-VIII)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once reduction is achieved, we suggest patients remain in the initial sugar tong splint for the following two to three weeks. The U-shaped part of the splint wraps around the elbow, thereby minimizing forearm rotation and maintaining the desired pronation or supination, according to the fracture type. The sugar tong splint also immobilizes the distal radioulnar joint (DRUJ), and splinted patients experience less pain than patients immobilized in a short arm cast [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographs are taken in the sugar tong splint on the third, seventh, and twelfth days following reduction. This enables the clinician to detect quickly any loss of position and to assess the acceptability of any postreduction movement or residual deformity. During the first two weeks, the initial splint should be adapted and molded as soft tissue swelling decreases. This is achieved by wrapping the splint tighter with elastic bandages at each follow-up visit. Adequate tightness and molding throughout the early postreduction period reduces the risk of secondary displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At two to three weeks, the splint is changed to a short arm cast. Wrist immobilization continues in the cast for another three to four weeks. The clinician must take care to maintain three point contact, and to avoid inadequate or excessively bulky padding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/28\">",
"     28",
"    </a>",
"    ]. At each visit, the clinician should assess fracture site tenderness, swelling, elbow and hand motion, and median nerve function. Radiographs should be obtained every two weeks and studied for signs of dorsal displacement, palmar angulation, and radial shortening [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be immobilized six to eight weeks, until there is evidence of radiographic healing and the fracture site is nontender. At this point, the clinician can remove the cast and place the patient in a wrist brace. Complete healing generally occurs within 8 to 12 weeks. The shortest possible period of immobilization is preferred for older patients; prolonged immobilization can cause joint stiffness and significant loss of function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the cast is removed, patients should begin active range-of-motion exercises. Physical therapy may be needed to achieve acceptable motion, but most patients require only a single session of instruction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/31\">",
"     31",
"    </a>",
"    ]. Older patients and those with more complicated fractures requiring prolonged immobilization may require more extensive rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294113819\">",
"    <span class=\"h2\">",
"     Styloid fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, large ulnar styloid fractures (ie, most or all of the styloid is involved) with displaced fragments at the styloid base should be referred to an orthopedic or hand surgeon, as they are associated with an increased risk of distal radioulnar joint (DRUJ) instability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/16,17,32,33\">",
"     16,17,32,33",
"    </a>",
"    ]. Fractures of the tip of the ulnar styloid, distal to the DRUJ, are generally considered stable and can be managed conservatively. Radial styloid fractures are often associated with scapholunate injuries and such fractures are generally referred to an orthopedic or hand surgeon for possible surgical management. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Isolated nondisplaced fractures of the ulnar styloid that do not involve the DRUJ and are not associated with DRUJ instability are uncommon, but can be managed conservatively in a short arm cast, as is done for nondisplaced radial fractures generally. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Nondisplaced extra-articular (Frykman types I/II)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Geriatric management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fracture management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vigorous elderly patients with distal radius fractures should be referred for surgical treatment as indicated. However, many older patients are best served by conservative fracture management and rehabilitation designed to maximize function, despite the presence of significant deformity. One study of patients older than 70 years of age who declined operative repair of their intraarticular distal radius fractures found 89 percent had a good or excellent functional outcome, despite 26 percent having only a fair or poor anatomic result [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study of elderly patients with moderately displaced Colles' fractures randomized to reduction under Bier block and immobilization or to immobilization alone found no functional difference between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/35\">",
"     35",
"    </a>",
"    ]. On average, two-thirds of the dorsal angulation corrected by manipulation was lost by five weeks. The authors concluded that up to 30 degrees of dorsal angulation and 5 mm of radial shortening may be accepted in selected elderly patients.",
"   </p>",
"   <p>",
"    The limited utility of fracture reduction among low-functioning geriatric patients was confirmed in another study of 59 patients with a mean age of 82 years. Of 60 fractures treated by closed reduction, 53 ultimately healed with significant deformity. Of 44 dorsally displaced fractures, reduction failed in seven cases initially, and 37 lost reduction during the following weeks of immobilization. The authors concluded that reduction of fractures of the distal radius is of minimal value in old and frail, dependent, or demented patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteoporosis also complicates management of older patients with fractures. Optimal clinical results of distal radius fractures have been shown to correlate more closely with bone mineral density than with radiographic parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/37\">",
"     37",
"    </a>",
"    ]. Osteoporosis contributes to fracture instability. We suggest patients with displaced fractures in osteoporotic bone be referred to an experienced orthopedist. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Regardless of management strategy, clinicians should minimize the length of time geriatric patients are immobilized because of the risk of joint stiffness and consequent disability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Osteoporosis evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture in an elderly individual warrants an evaluation for osteoporosis. A history of a fracture is an important risk factor for a subsequent fracture. Unfortunately, the majority of patients with vertebral, hip, and distal radius fractures do not receive evaluation and treatment for underlying osteoporosis. As a result, these patients frequently suffer additional fractures. Elderly patients with a history of fracture constitute a high-risk group that requires additional evaluation and treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H38#H38\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Medical intervention after fracture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Early complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Median nerve injury and, although rare, compartment syndrome and vascular compromise are the most important early complications of distal radius fractures.",
"   </p>",
"   <p>",
"    Acute carpal tunnel syndrome (ACTS) is found more frequently with severely comminuted or displaced fractures, patients treated with multiple reductions, and those splinted in extreme wrist flexion (&gt;15 degrees) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/38\">",
"     38",
"    </a>",
"    ]. The clinician must perform a careful neurologic examination looking for signs of ACTS at the initial and first follow-up visits, and initial visits following any remanipulation. Weakness or loss of thumb or index finger flexion is the most important finding. Carpal tunnel release is indicated if symptoms progress, with or without reduction, or if surgical fixation is planned. Results are best if release is performed urgently [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .) A mild sensory deficit consistent with median nerve contusion is often observed and generally is not caused by ACTS.",
"   </p>",
"   <p>",
"    The interval from injury to development of compartment syndrome may range from 12 to 54 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Increasing or constant severe pain and pain elicited by passive extension of the fingers are important findings, but measurement of elevated compartment pressures provides a definitive diagnosis. Emergent fasciotomy is required. A more detailed discussion is found elsewhere. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Complications of closed reduction and cast treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Vascular injuries are rare in closed fractures, but injury to the radial or ulnar artery has been reported in high-energy injuries with significant fracture displacement. Perfusion often improves with reduction, but emergent vascular surgery evaluation is necessary for any persistent impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injuries to carpal bones and carpal ligaments occasionally accompany distal radius fractures, and they should be suspected in patients with persistent wrist pain despite acceptable alignment. A case series of 565 Colles' fractures revealed scaphoid fractures were initially missed in 0.7 percent of cases and intercarpal ligament injuries in 0.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/44\">",
"     44",
"    </a>",
"    ]. Scaphoid fractures in association with distal radius fractures should be treated with internal fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/18\">",
"     18",
"    </a>",
"    ]. Failure to identify and treat scapholunate ligament injuries with acute pinning has been shown to adversely affect outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/19\">",
"     19",
"    </a>",
"    ]. Fracture lines that involve the radial articular surface near the scapholunate ligament should raise suspicion of scapholunate ligament injury (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52517 \" href=\"UTD.htm?14/30/14816\">",
"     image 6",
"    </a>",
"    ). If initial radiographs show normal scapholunate distance but suspicion is high, we suggest placing a thumb spica, in addition to appropriate wrist immobilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Complications of closed reduction and cast treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin tearing can occur with over-vigorous manual reduction and also with the use of older, metal finger traps. Skin rarely tears with the newer, cloth finger traps. If metal skin traps are used, cloth tape can be placed over the fingers before they are hung to reduce skin injury [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Closed extremity fractures place patients at risk for compartment syndrome, although it is an uncommon complication of distal radius fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Patients with compartment syndrome complain of increasing or constant severe pain and paresthesias. One potential warning sign may be increasing analgesic use. The clinician generally can palpate a firm, tense forearm, and can elicit pain by passive extension of the fingers, thereby stretching the flexor tendons within the forearm compartment. Measurement of elevated compartment pressures enables more accurate diagnosis. Normal pressure is less than 5 mmHg; pressure exceeding 30 mmHg generally warrants emergent fasciotomy. Alterations in capillary refill, distal pulses, and skin color are",
"    <strong>",
"     NOT",
"    </strong>",
"    reliable findings. Clinicians should warn patients about the symptoms of compartment syndrome and consider it in patients who complain of severe pain in the days immediately following fracture reduction.",
"   </p>",
"   <p>",
"    Reports exist of compartment syndrome following closed reduction under local hematoma block [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/46\">",
"     46",
"    </a>",
"    ], but it is a rare complication, and the role of the hematoma block has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/10\">",
"     10",
"    </a>",
"    ]. Staphylococcus aureus osteomyelitis following hematoma block has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/47\">",
"     47",
"    </a>",
"    ]. Attention to sterile technique and to the amount of local anesthetic injected should minimize these complications.",
"   </p>",
"   <p>",
"    Splinting the wrist in palmar flexion greater than 15 degrees increases the risk of ACTS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/48\">",
"     48",
"    </a>",
"    ] and complex regional pain syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/49\">",
"     49",
"    </a>",
"    ]. Careful splinting that allows full flexion and extension of the metacarpal phalangeal (MCP) joints is important to prevent MCP joint contractures and proximal tendon adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent sensory neuropathy following distal radius fracture can occur due to median nerve contusion at the time of injury or reduction, but it correlates closely with fracture malunion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/50\">",
"     50",
"    </a>",
"    ]. Surgical treatment with osteotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/51\">",
"     51",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    release of the median nerve is indicated for persistent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tendon inflammation and rupture can occur with closed cast treatment. Rupture of the extensor pollicis longus (EPL) tendon is most common, with an incidence of 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/53\">",
"     53",
"    </a>",
"    ] to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], and it occurs between two weeks and 11 months (average seven weeks) after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/54\">",
"     54",
"    </a>",
"    ]. Diagnosis is usually made after rupture, and treatment is surgical. EPL rupture is more common with minimally displaced fractures. Tendonitis of the first dorsal compartment and of the extensor carpi ulnaris can also be seen after distal radius fracture. This is usually responsive to steroid injection, but it must be differentiated from triangular fibrocartilage tear or other ulnocarpal ligamentous injury [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Long-term outcomes/complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of variables related to patient characteristics, fracture type, and radiographic findings predispose patients to the development of osteoarthritis and disability. Major complications are discussed below. The incidence of complex regional pain syndrome, another potential complication, may be reduced by prophylactic vitamin C, and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevention and management of complex regional pain syndrome in adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraarticular fractures that are reduced to acceptable alignment rarely cause radiocarpal osteoarthritis. For fractures with intraarticular extension, there is a significant association between residual displacement of articular fragments at the time of bony union and the development of radiocarpal osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/56\">",
"     56",
"    </a>",
"    ]. In one case series, 100 percent of fractures with articular step-off of 2 mm or more developed radiographic evidence of osteoarthritis, compared with only 11 percent of those that healed with a congruous joint [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/57\">",
"     57",
"    </a>",
"    ]. A second series found that a step-off of only 1 mm predisposed patients to radiocarpal osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Residual disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term disability has been correlated with a number of radiographic parameters and fracture characteristics. One series found a close correlation between the degree of postinjury radial shortening and disability: 4 percent of patients with normal height had poor function, whereas 25 percent of patients with 3 to 5 mm of radial shortening and 31 percent of patients with more than 5 mm of radial shortening had poor function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Dorsal angulation alone influenced early but not 10-year function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/60\">",
"     60",
"    </a>",
"    ], but dorsal angulation of greater than 15 degrees combined with more than 2 mm radial shortening compromised outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. More than 10 degrees of dorsal tilt leads to a dorsal carpal shift with compressive forces, causing pain and insecurity with gripping, even during everyday activities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/63\">",
"     63",
"    </a>",
"    ]. Grip strength correlates inversely with the degree of osteoarthrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Incongruency of the distal radioulnar joint (DRUJ) from residual dorsal angulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/65\">",
"     65",
"    </a>",
"    ] or positive ulnar variance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/66\">",
"     66",
"    </a>",
"    ] has been associated with wrist pain. Triangular fibrocartilage complex (TFCC) tears occur not infrequently with distal radius fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/67\">",
"     67",
"    </a>",
"    ], and greater radial shortening and dorsal angulation is found in patients with TFCC tears (",
"    <a class=\"graphic graphic_figure graphicRef80101 \" href=\"UTD.htm?0/13/211\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/68\">",
"     68",
"    </a>",
"    ]. A TFCC tear has occurred if the distal radius is shortened by more than 2.7 mm. TFCC tears are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the adult with acute wrist pain\", section on 'Other traumatic injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The extent of fracture comminution and articular involvement correlates with loss of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/63\">",
"     63",
"    </a>",
"    ]. Range of motion loss after immobilization should be treated with aggressive physical therapy, unless it is caused by bony malalignment, in which case prolonged therapy is of no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distal radius fractures frequently occur at work or under circumstances that allow for financial compensation. Injury compensation was shown in one study to be the best predictor of pain and disability at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/69\">",
"     69",
"    </a>",
"    ]. Another author found that patients with work-related injuries were more than four times less likely to return to work than those injured while away from work [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients receiving compensation for their injuries are likely to have poorer outcomes regardless of the anatomic result [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One important message to be gleaned from these data is that, with the exception of a subset of low-functioning geriatric patients, clinicians should aggressively seek to achieve congruent joint reduction and to prevent excessive loss of radial length or abnormal tilt of the radial articular surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Patient satisfaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors most responsible for patient satisfaction remain unclear. Some claim patient satisfaction depends more on hand dominance and residual wrist pain than range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/70\">",
"     70",
"    </a>",
"    ]. Others have found grip power [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/71\">",
"     71",
"    </a>",
"    ] and return of wrist function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/72\">",
"     72",
"    </a>",
"    ] most significant. A study of operative patients found satisfaction correlated better with pain relief and grip strength than postoperative radiographic parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?21/13/21722/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to work is determined by the severity of injury and the tasks involved. Patients with sedentary jobs may return immediately; physical laborers may return to full duty only after they have regained near-normal wrist motion and strength. It is reasonable for participants in contact sports also to delay return to play until they have achieved near-normal motion and strength, and to wear a protective palmar splint during the first few weeks of play.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"       \"Patient information: Common wrist injuries (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal radius fractures are extremely common. Fractures in younger patients are the result of high-energy trauma, often during sports. Fractures in older patients are frequently the result of low-energy trauma to osteoporotic bone. The typical mechanism for distal radius fracture is a Fall Onto an Out-Stretched Hand (FOOSH). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination at the time of injury should include inspection for open fractures and deformity, assessment of wrist motion (if possible), and evaluation for associated injuries, such as scaphoid fracture or scapholunate ligament injury. The wrist may appear normal despite the presence of a fracture. In the days following injury or fracture manipulation, clinicians should pay close attention to neurovascular status (particularly median nerve function) and beware of acute compartment syndrome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is typically made by x-ray. Clinicians should study the standard plan radiographs of the wrist, including anterior-posterior (AP), lateral, and oblique views, looking for any loss of normal anatomy, the presence and degree of joint involvement (including both radiocarpal and distal radioulnar joints), and the presence of any high-risk features (eg, comminution, articular step-off &gt;2 mm). Abnormal measurements of radial inclination, radial height, palmar tilt, or ulnar variance suggest significant injury. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent orthopedic referral is required for the following conditions (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Open fractures",
"     </li>",
"     <li>",
"      Acute compression neuropathy or compartment syndrome",
"     </li>",
"     <li>",
"      Vascular compromise despite reduction (emergent vascular surgery referral may also be required in this circumstance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unstable fractures and those at high risk for complications should be referred to an orthopedic surgeon. We recommend that fractures associated with the following conditions be referred to a knowledgeable orthopedist (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Palmar displacement",
"     </li>",
"     <li>",
"      Radial articular step-off greater than 2 mm, or involvement of the articular surface of the distal radial ulnar joint",
"     </li>",
"     <li>",
"      Large ulnar styloid fractures with displaced fragments at the styloid base",
"     </li>",
"     <li>",
"      Greater than 20 degrees of dorsal angulation",
"     </li>",
"     <li>",
"      Displacement in any direction greater than two-thirds the width of the radial shaft",
"     </li>",
"     <li>",
"      Metaphyseal comminution with more than 5 mm of radial shortening (normal height = 10 to 13 mm)",
"     </li>",
"     <li>",
"      Ulnar variance greater than 5 mm compared with the contralateral wrist (normal variance is 0 to -2 mm)",
"     </li>",
"     <li>",
"      Associated scaphoid fractures or scapholunate ligament injuries",
"     </li>",
"     <li>",
"      Fracture-dislocations (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Fracture dislocations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Advanced osteoporosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nondisplaced extraarticular fractures are relatively stable, and treatment is straightforward. We suggest the following approach for acute management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H14\">",
"       'Initial treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Place the arm in a well-molded sugar tong, reverse sugar tong, or double sugar tong splint (",
"      <strong>",
"       NOT",
"      </strong>",
"      a circumferential cast), with the arm in neutral position (ie, without forearm supination or pronation, and without wrist flexion or extension). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H12#H12\">",
"       \"Splinting of musculoskeletal injuries\", section on 'Sugar tong splints'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevate the arm.",
"     </li>",
"     <li>",
"      Apply ice to the fracture frequently (while keeping the splint dry).",
"     </li>",
"     <li>",
"      Begin active range of motion of the shoulder and fingers.",
"     </li>",
"     <li>",
"      Use analgesics as needed. Opioids may be necessary; a short course of nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Displaced fractures with neurovascular compromise warrant an immediate attempt at closed reduction. Immediate closed reduction by an experienced clinician is appropriate, but not required, for displaced fractures without neurovascular compromise or radiographic evidence of instability. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a clinician capable of performing a reduction is unavailable and there is no neurovascular compromise, the provider may immobilize the fracture, provide appropriate analgesia, and discharge the patient, provided follow-up the next day for reduction by an orthopedist has been arranged.",
"     </li>",
"     <li>",
"      Our recommendations for postreduction care of displaced fractures do not differ from that of nondisplaced injuries described immediately above. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Criteria for adequate reduction in a patient with high functional demands include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No dorsal tilt of the distal radial articular surface",
"     </li>",
"     <li>",
"      Less than 5 mm of radial shortening",
"     </li>",
"     <li>",
"      Less than 2 mm of displacement of fracture fragments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splints and casts should not place the wrist in palmar flexion greater than 15 degrees, and they should allow full flexion and extension of the metacarpal phalangeal (MCP) joints to prevent complications.",
"     </li>",
"     <li>",
"      A schedule for follow-up care, including timing of radiographs, is provided for both displaced and nondisplaced fractures. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vigorous elderly patients with distal radius fractures should be referred for surgical treatment as indicated. However, many older patients are best served by conservative fracture management (ie, without manipulation or fixation) and rehabilitation designed to maximize function, despite the presence of significant deformity. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Geriatric management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications from distal radius fractures fall into two main categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early complications include acute carpal tunnel syndrome, vascular injury, and compartment syndrome. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Early complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Complications of closed reduction and cast treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late complications include tendon irritation and rupture (especially of the extensor pollicis longus), osteoarthritis, wrist pain or instability, and loss of motion. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Long-term outcomes/complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor functional outcome correlates with abnormal anatomy. With the exception of a subset of low-functioning geriatric patients, clinicians should aggressively seek to achieve congruent joint reduction and to prevent excessive loss of radial length or abnormal tilt of the radial articular surface. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Long-term outcomes/complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/1\">",
"      Chung KC, Spilson SV. The frequency and epidemiology of hand and forearm fractures in the United States. J Hand Surg Am 2001; 26:908.",
"     </a>",
"    </li>",
"    <li>",
"     Eiff MP, Hatch RL, Calmbach WL. Carpal fractures. In: Fracture Management for Primary Care, 2nd, Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/3\">",
"      Lawson GM, Hajducka C, McQueen MM. Sports fractures of the distal radius--epidemiology and outcome. Injury 1995; 26:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/4\">",
"      Matsumoto K, Sumi H, Sumi Y, Shimizu K. Wrist fractures from snowboarding: a prospective study for 3 seasons from 1998 to 2001. Clin J Sport Med 2004; 14:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/5\">",
"      O'Neill TW, Cooper C, Finn JD, et al. Incidence of distal forearm fracture in British men and women. Osteoporos Int 2001; 12:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/6\">",
"      Vogt MT, Cauley JA, Tomaino MM, et al. Distal radius fractures in older women: a 10-year follow-up study of descriptive characteristics and risk factors. The study of osteoporotic fractures. J Am Geriatr Soc 2002; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/7\">",
"      Haentjens P, Johnell O, Kanis JA, et al. Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res 2004; 19:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/8\">",
"      Rozental TD, Branas CC, Bozentka DJ, Beredjiklian PK. Survival among elderly patients after fractures of the distal radius. J Hand Surg Am 2002; 27:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/9\">",
"      Khan SA, de Geus C, Holroyd B, Russell AS. Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med 2001; 161:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/10\">",
"      Gutow AP. Avoidance and treatment of complications of distal radius fractures. Hand Clin 2005; 21:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/11\">",
"      Andersen DJ, Blair WF, Steyers CM Jr, et al. Classification of distal radius fractures: an analysis of interobserver reliability and intraobserver reproducibility. J Hand Surg Am 1996; 21:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/12\">",
"      Bozentka DJ, Beredjiklian PK, Westawski D, Steinberg DR. Digital radiographs in the assessment of distal radius fracture parameters. Clin Orthop Relat Res 2002; :409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/13\">",
"      Medoff RJ. Essential radiographic evaluation for distal radius fractures. Hand Clin 2005; 21:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/14\">",
"      Louis DS. Barton's and Smith's fractures. Hand Clin 1988; 4:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/15\">",
"      Mehara AK, Rastogi S, Bhan S, Dave PK. Classification and treatment of volar Barton fractures. Injury 1993; 24:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/16\">",
"      May MM, Lawton JN, Blazar PE. Ulnar styloid fractures associated with distal radius fractures: incidence and implications for distal radioulnar joint instability. J Hand Surg Am 2002; 27:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/17\">",
"      Lindau T. Treatment of injuries to the ulnar side of the wrist occurring with distal radial fractures. Hand Clin 2005; 21:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/18\">",
"      Trumble TE, Benirschke SK, Vedder NB. Ipsilateral fractures of the scaphoid and radius. J Hand Surg Am 1993; 18:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/19\">",
"      Stoffelen D, De Mulder K, Broos P. The clinical importance of carpal instabilities following distal radial fractures. J Hand Surg Br 1998; 23:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/20\">",
"      Lafontaine M, Hardy D, Delince P. Stability assessment of distal radius fractures. Injury 1989; 20:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/21\">",
"      Altissimi M, Mancini GB, Azzar&agrave; A, Ciaffoloni E. Early and late displacement of fractures of the distal radius. The prediction of instability. Int Orthop 1994; 18:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/22\">",
"      Adolphson P, Abbaszadegan H, Jonsson U. Computer-assisted prediction of the instability of Colles' fractures. Int Orthop 1993; 17:13.",
"     </a>",
"    </li>",
"    <li>",
"     MacKenney PJ, McQueen MM, Elton R. Prediction of instability of fractures of the distal radius. Presented at the Orthopedic Trauma Association, Session I, Charlotte, NC, October 22, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/24\">",
"      Jeong GK, Kaplan FT, Liporace F, et al. An evaluation of two scoring systems to predict instability in fractures of the distal radius. J Trauma 2004; 57:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/25\">",
"      Nesbitt KS, Failla JM, Les C. Assessment of instability factors in adult distal radius fractures. J Hand Surg Am 2004; 29:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/26\">",
"      Earnshaw SA, Aladin A, Surendran S, Moran CG. Closed reduction of colles fractures: comparison of manual manipulation and finger-trap traction: a prospective, randomized study. J Bone Joint Surg Am 2002; 84-A:354.",
"     </a>",
"    </li>",
"    <li>",
"     Chamley J. The Closed Treatment of Common Fractures, Williams &amp; Wilkins, Baltimore 1961.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/28\">",
"      Fernandez DL. Closed manipulation and casting of distal radius fractures. Hand Clin 2005; 21:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/29\">",
"      Handoll HH, Madhok R. Conservative interventions for treating distal radial fractures in adults. Cochrane Database Syst Rev 2003; :CD000314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/30\">",
"      O'Connor D, Mullett H, Doyle M, et al. Minimally displaced Colles' fractures: a prospective randomized trial of treatment with a wrist splint or a plaster cast. J Hand Surg Br 2003; 28:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/31\">",
"      Maciel JS, Taylor NF, McIlveen C. A randomised clinical trial of activity-focussed physiotherapy on patients with distal radius fractures. Arch Orthop Trauma Surg 2005; 125:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/32\">",
"      Sammer DM, Chung KC. Management of the distal radioulnar joint and ulnar styloid fracture. Hand Clin 2012; 28:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/33\">",
"      Logan AJ, Lindau TR. The management of distal ulnar fractures in adults: a review of the literature and recommendations for treatment. Strategies Trauma Limb Reconstr 2008; 3:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/34\">",
"      Dayican A, Unal VS, Ozkurt B, et al. Conservative treatment in intra-articular fractures of the distal radius: a study on the functional and anatomic outcome in elderly patients. Yonsei Med J 2003; 44:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/35\">",
"      Kelly AJ, Warwick D, Crichlow TP, Bannister GC. Is manipulation of moderately displaced Colles' fracture worthwhile? A prospective randomized trial. Injury 1997; 28:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/36\">",
"      Beumer A, McQueen MM. Fractures of the distal radius in low-demand elderly patients: closed reduction of no value in 53 of 60 wrists. Acta Orthop Scand 2003; 74:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/37\">",
"      Hollevoet N, Verdonk R. Outcome of distal radius fractures in relation to bone mineral density. Acta Orthop Belg 2003; 69:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/38\">",
"      Br&uuml;ske J, Niedwied Z, Bednarski M, Zyluk A. [Acute carpal tunnel syndrome after distal radius fractures--long term results of surgical treatment with decompression and external fixator application]. Chir Narzadow Ruchu Ortop Pol 2002; 67:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/39\">",
"      Ford DJ, Ali MS. Acute carpal tunnel syndrome. Complications of delayed decompression. J Bone Joint Surg Br 1986; 68:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/40\">",
"      Mack GR, McPherson SA, Lutz RB. Acute median neuropathy after wrist trauma. The role of emergent carpal tunnel release. Clin Orthop Relat Res 1994; :141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/41\">",
"      Stockley I, Harvey IA, Getty CJ. Acute volar compartment syndrome of the forearm secondary to fractures of the distal radius. Injury 1988; 19:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/42\">",
"      Simpson NS, Jupiter JB. Delayed onset of forearm compartment syndrome: a complication of distal radius fracture in young adults. J Orthop Trauma 1995; 9:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/43\">",
"      Wang AA, Strauch RJ, Moore JA. Pseudoaneurysm of the ulnar artery occurring after fracture of the distal radius and ulna: a case report. J Hand Surg Am 1998; 23:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/44\">",
"      Cooney WP 3rd, Dobyns JH, Linscheid RL. Complications of Colles' fractures. J Bone Joint Surg Am 1980; 62:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/45\">",
"      Guiral J, Acosta JP, De Benito JI. [Acute compartment syndrome as a complication of a distal forearm fracture: apropos of a case of a child]. Rev Chir Orthop Reparatrice Appar Mot 1995; 81:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/46\">",
"      Younge D. Haematoma block for fractures of the wrist: a cause of compartment syndrome. J Hand Surg Br 1989; 14:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/47\">",
"      Basu A, Bhalaik V, Stanislas M, Harvey IA. Osteomyelitis following a haematoma block. Injury 2003; 34:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/48\">",
"      Dresing K, Peterson T, Schmit-Neuerburg KP. Compartment pressure in the carpal tunnel in distal fractures of the radius. A prospective study. Arch Orthop Trauma Surg 1994; 113:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/49\">",
"      Placzek JD, Boyer MI, Gelberman RH, et al. Nerve decompression for complex regional pain syndrome type II following upper extremity surgery. J Hand Surg Am 2005; 30:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/50\">",
"      Aro H, Koivunen T, Katevuo K, et al. Late compression neuropathies after Colles' fractures. Clin Orthop Relat Res 1988; :217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/51\">",
"      Roesgen M, Hierholzer G. Corrective osteotomy of the distal radius after fracture to restore the function of wrist joint, forearm, and hand. Arch Orthop Trauma Surg 1988; 107:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/52\">",
"      Lewis MH. Median nerve decompression after Colles's fracture. J Bone Joint Surg Br 1978; 60-B:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/53\">",
"      Hove LM. Delayed rupture of the thumb extensor tendon. A 5-year study of 18 consecutive cases. Acta Orthop Scand 1994; 65:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/54\">",
"      Bonatz E, Kramer TD, Masear VR. Rupture of the extensor pollicis longus tendon. Am J Orthop (Belle Mead NJ) 1996; 25:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/55\">",
"      Skoff HD. Postfracture extensor pollicis longus tenosynovitis and tendon rupture: a scientific study and personal series. Am J Orthop (Belle Mead NJ) 2003; 32:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/56\">",
"      Catalano LW 3rd, Cole RJ, Gelberman RH, et al. Displaced intra-articular fractures of the distal aspect of the radius. Long-term results in young adults after open reduction and internal fixation. J Bone Joint Surg Am 1997; 79:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/57\">",
"      Knirk JL, Jupiter JB. Intra-articular fractures of the distal end of the radius in young adults. J Bone Joint Surg Am 1986; 68:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/58\">",
"      Fernandez JJ, Gruen GS, Herndon JH. Outcome of distal radius fractures using the short form 36 health survey. Clin Orthop Relat Res 1997; :36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/59\">",
"      Aro HT, Koivunen T. Minor axial shortening of the radius affects outcome of Colles' fracture treatment. J Hand Surg Am 1991; 16:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/60\">",
"      Warwick D, Field J, Prothero D, et al. Function ten years after Colles' fracture. Clin Orthop Relat Res 1993; :270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/61\">",
"      Leung F, Ozkan M, Chow SP. Conservative treatment of intra-articular fractures of the distal radius--factors affecting functional outcome. Hand Surg 2000; 5:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/62\">",
"      Batra S, Gupta A. The effect of fracture-related factors on the functional outcome at 1 year in distal radius fractures. Injury 2002; 33:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/63\">",
"      Gliatis JD, Plessas SJ, Davis TR. Outcome of distal radial fractures in young adults. J Hand Surg Br 2000; 25:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/64\">",
"      Hove LM, Fjeldsgaard K, Skjeie R, Solheim E. Anatomical and functional results five years after remanipulated Colles' fractures. Scand J Plast Reconstr Surg Hand Surg 1995; 29:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/65\">",
"      Tsukazaki T, Iwasaki K. Ulnar wrist pain after Colles' fracture. 109 fractures followed for 4 years. Acta Orthop Scand 1993; 64:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/66\">",
"      Hollevoet N, Verdonk R. The functional importance of malunion in distal radius fractures. Acta Orthop Belg 2003; 69:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/67\">",
"      Geissler WB, Freeland AE, Savoie FH, et al. Intracarpal soft-tissue lesions associated with an intra-articular fracture of the distal end of the radius. J Bone Joint Surg Am 1996; 78:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/68\">",
"      Richards RS, Bennett JD, Roth JH, Milne K Jr. Arthroscopic diagnosis of intra-articular soft tissue injuries associated with distal radial fractures. J Hand Surg Am 1997; 22:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/69\">",
"      MacDermid JC, Donner A, Richards RS, Roth JH. Patient versus injury factors as predictors of pain and disability six months after a distal radius fracture. J Clin Epidemiol 2002; 55:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/70\">",
"      Beaul&eacute; PE, Dervin GF, Giachino AA, et al. Self-reported disability following distal radius fractures: the influence of hand dominance. J Hand Surg Am 2000; 25:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/71\">",
"      Fujii K, Henmi T, Kanematsu Y, et al. Fractures of the distal end of radius in elderly patients: a comparative study of anatomical and functional results. J Orthop Surg (Hong Kong) 2002; 10:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/72\">",
"      Karnezis IA, Fragkiadakis EG. Association between objective clinical variables and patient-rated disability of the wrist. J Bone Joint Surg Br 2002; 84:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/13/21722/abstract/73\">",
"      Trumble TE, Wagner W, Hanel DP, et al. Intrafocal (Kapandji) pinning of distal radius fractures with and without external fixation. J Hand Surg Am 1998; 23:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 219 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21722=[""].join("\n");
var outline_f21_13_21722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Athletics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Geriatric population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H395494646\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anatomic landmarks and measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Posterior-anterior (PA) x-ray",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lateral x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fracture dislocations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H395494673\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H395494681\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nondisplaced extra-articular fractures (Frykman types I/II)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Displaced fractures (Frykman types I-VIII)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FRACTURE REDUCTION BASICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hematoma block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Reduction techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nondisplaced extra-articular (Frykman types I/II)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Displaced (Frykman types I-VIII)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H294113819\">",
"      Styloid fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Geriatric management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fracture management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Osteoporosis evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Early complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Complications of closed reduction and cast treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Long-term outcomes/complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Residual disability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Patient satisfaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/219|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/21/20817\" title=\"diagnostic image 1\">",
"      Distal radius measurements AP view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/1/6161\" title=\"diagnostic image 2\">",
"      Distal radius central reference point",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/34/8736\" title=\"diagnostic image 3\">",
"      Distal radius measurements lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/46/17135\" title=\"diagnostic image 4A\">",
"      Frykman I radius fracture AP view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/42/41646\" title=\"diagnostic image 4B\">",
"      Frykman I radius fracture lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/34/2607\" title=\"diagnostic image 4C\">",
"      Frykman I radius fracture oblique view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/39/25215\" title=\"diagnostic image 5A\">",
"      Frykman IV radius fracture AP view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/54/10095\" title=\"diagnostic image 5B\">",
"      Frykman IV radius fracture lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/30/14816\" title=\"diagnostic image 6\">",
"      Scapholunate dissociation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/219|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/24/28047\" title=\"figure 1\">",
"      Dinner fork deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/13/8407\" title=\"figure 2\">",
"      AP distal radius height",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/3/35890\" title=\"figure 3\">",
"      Lat distal radius volar tilt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/33/3615\" title=\"figure 4\">",
"      Finger trap fixture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/13/211\" title=\"figure 5\">",
"      Triangular fibrocartilage complex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/219|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/44/36547\" title=\"picture 1\">",
"      Palpation of scaphoid in anatomic snuffbox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14039?source=related_link\">",
"      Anatomy and basic biomechanics of the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14983?source=related_link\">",
"      Evaluation of elbow pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=related_link\">",
"      Evaluation of the adult with acute wrist pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=related_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=related_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=related_link\">",
"      Prevention and management of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=related_link\">",
"      Scaphoid fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_13_21723="Animal handling antigens in HP";
var content_f21_13_21723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypersensitivity pneumonitides associated with veterinary work and animal handling",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Environmental source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major causative antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laboratory worker's lung (rats, gerbils)",
"       </td>",
"       <td>",
"        Urine, serum, pelts, proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary snuff taker's disease",
"       </td>",
"       <td>",
"        Dried, powdered neurohypophysis (bovine and porcine pituitary proteins)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furrier's lung (sewing furs; animal fur dust)",
"       </td>",
"       <td>",
"        Animal pelts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bat lung (bat droppings)",
"       </td>",
"       <td>",
"        Bat serum protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fish meal worker's lung",
"       </td>",
"       <td>",
"        Fish meal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coptic lung (mummy handler's lung)",
"       </td>",
"       <td>",
"        Cloth wrappings of mummies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mollusc shell HP",
"       </td>",
"       <td>",
"        Sea-snail shell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pearl oyster shell pneumonitis",
"       </td>",
"       <td>",
"        Oyster shells",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21723=[""].join("\n");
var outline_f21_13_21723=null;
var title_f21_13_21724="Comorbidity of bulimia nervosa and other DSM-IV Axis I disorders";
var content_f21_13_21724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F63449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F63449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lifetime comorbidity of bulimia nervosa with other DSM-IV Axis I disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Axis I disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of bulimia nervosa",
"        <br/>",
"        patients with a comorbid disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Anxiety disorder",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Specific phobia",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Posttraumatic stress disorder",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Social phobia",
"       </td>",
"       <td>",
"        41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obsessive-compulsive disorder",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Mood disorder",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unipolar major depression",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bipolar disorder",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysthymic disorder",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Impulse control disorder",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Attention-deficit/hyperactivity disorder",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oppositional-defiant disorder",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conduct disorder",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Substance use disorder",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol abuse or dependence",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Illicit drug abuse or dependence",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61:348.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21724=[""].join("\n");
var outline_f21_13_21724=null;
var title_f21_13_21725="USPSTF grade D recommendations";
var content_f21_13_21725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adult screening and prevention recommendations of USPSTF (August 2012) D recommendations (discourage testing)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Service",
"       </td>",
"       <td class=\"subtitle1\">",
"        Population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for abdominal aortic aneurysm",
"       </td>",
"       <td>",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirin to prevent CVD",
"       </td>",
"       <td>",
"        Men under age 45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirin to prevent ischemic stroke",
"       </td>",
"       <td>",
"        Women under age 55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for asymptomatic carotid artery stenosis",
"       </td>",
"       <td>",
"        Adult men and women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for coronary heart disease (ECG, ETT, or EBCT)",
"       </td>",
"       <td>",
"        Adults not at increased risk",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for peripheral arterial disease",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chemoprevention of breast cancer",
"       </td>",
"       <td>",
"        Women not at increased risk of breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for breast cancer by teaching BSE",
"       </td>",
"       <td>",
"        All women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BRCA mutation testing for breast and ovarian cancer",
"       </td>",
"       <td>",
"        Women whose family history is not associated with an increased risk for deleterious mutations in BRCA 2 or BRCA 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for bladder cancer",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cervical cancer screening with Pap smear",
"       </td>",
"       <td>",
"        Women over age 65 who have had previous negative screens; women who have had total hysterectomy for benign disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for colorectal cancer",
"       </td>",
"       <td>",
"        Men and women ages 86 years and older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirin and NSAIDs to prevent colorectal cancer",
"       </td>",
"       <td>",
"        Men under age 45; women under age 55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for ovarian cancer",
"       </td>",
"       <td>",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for pancreatic cancer",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for prostate cancer",
"       </td>",
"       <td>",
"        All men",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for testicular cancer",
"       </td>",
"       <td>",
"        Men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Sexually transmitted infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for bacterial vaginosis",
"       </td>",
"       <td>",
"        Average risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serologic screening for genital herpes simplex",
"       </td>",
"       <td>",
"        Asymptomatic pregnant women; asymptomatic adolescents and adults",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for syphilis",
"       </td>",
"       <td>",
"        Not at increased risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for asymptomatic bacteriuria",
"       </td>",
"       <td>",
"        Men and non-pregnant women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beta carotene supplements",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for chronic obstructive pulmonary disease with spirometry",
"       </td>",
"       <td>",
"        Adult men and women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for hepatitis B infection",
"       </td>",
"       <td>",
"        General population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for hepatitis C infection",
"       </td>",
"       <td>",
"        Not at increased risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postmenopausal hormone therapy for primary prevention of chronic problems",
"       </td>",
"       <td>",
"        Postmenopausal women with or without a hysterectomy: estrogen plus progestin or estrogen alone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for idiopathic scoliosis",
"       </td>",
"       <td>",
"        Adolescents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     D: discourage, unless unusual additional considerations; ECT: electrocardiogram; ETT: exercise tolerance test; EBCT: electron beam CT for coronary calcification; BSE: breast self-examination; USPSTF: United States Preventive Services Task Force.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21725=[""].join("\n");
var outline_f21_13_21725=null;
var title_f21_13_21726="Contents: Psychiatric disorders";
var content_f21_13_21726=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Psychiatric disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Psychiatric disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Attention deficit hyperactivity disorder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/63/32761\">",
"           Adult attention deficit hyperactivity disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20599\">",
"           Pharmacotherapy for adult ADHD",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Delirium",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eating disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/38/7781\">",
"           Eating disorders in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/2/23593\">",
"           Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44023\">",
"           Eating disorders: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Emergencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Grief and bereavement",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/4/3145\">",
"           Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/3/29751\">",
"           Overview of psychotherapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/14/22760\">",
"           Pathologic gambling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/52/22343\">",
"           Psychological stress and infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/34/1575\">",
"           Treatment of delusional parasitosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mood disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21145\">",
"           Medical consultation for electroconvulsive therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Personality disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/19/10553\">",
"           Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/1/42009\">",
"           Borderline personality disorder: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/55/40824\">",
"           Personality disorders",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/11/20666\">",
"           Postpartum blues and depression",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychotic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28583\">",
"           Overview of psychosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/47/34552\">",
"           Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Somatoform disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/21/7512\">",
"           Factitious disorder and Munchausen syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27242\">",
"           Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10617\">",
"           Primary care management of medically unexplained symptoms",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Substance use disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36521\">",
"           Dual diagnosis: Severe mental illness and substance use disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/27/5562\">",
"           Impaired healthcare provider",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1191\">",
"           Opioid detoxification during treatment for addiction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/51/3897\">",
"           Opioid intoxication in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/5/28758\">",
"           Opioid withdrawal in the emergency setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38874\">",
"           Overview of the risks and benefits of alcohol consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41847\">",
"           Psychosocial treatment of alcohol abuse and dependence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/58/5033\">",
"           Substance use disorders: Principles for recognition and assessment in general medical care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29514\">",
"           Treatment of opioid abuse and dependence",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-B8543360F3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_13_21726=[""].join("\n");
var outline_f21_13_21726=null;
var title_f21_13_21727="Comminuted femoral shaft fracture";
var content_f21_13_21727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comminuted femoral shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Klane White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_13_21727=[""].join("\n");
var outline_f21_13_21727=null;
     